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Computers are routinely used in the 
modern drug discovery process. In 
virtual screening, the bioactivity of a 
compound is predicted in silico. The 
focus of this study has been in the 
development of novel rapid virtual 
screening software and acceleration 
of current methods. This dissertation 
describes new approaches for both 
protein- and ligand-based virtual 
screening.
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Kalliokoski, Tuomo. Accelerating Three-Dimensional Virtual Screening: New 
Software and Approaches for Computer-Aided Drug Discovery. Publications 
of the University of Eastern Finland. Dissertations in Health Sciences, 22. 2010. 
174 p. 
ABSTRACT 
Computers are routinely used in the drug discovery process. Virtual screening 
is defined to be the selection of compounds by evaluating their desirability in a 
computational model. Usually the predicted property is the bioactivity of a 
compound in an in vitro assay. Based on the classic Fischer lock and key-
model, virtual screening is either ligand- or structure-based. In three-
dimensional virtual screening, models of ligands and/or target proteins are 
used. In the ligand-based approach, the similarity of known ligands is used in 
the search for novel structures, whereas in structure-based virtual screening, 
compounds are docked into a protein model of the drug target. A 
consideration of all three-dimensions increases the computational expense of 
virtual screening considerably. The predictions need to be fast, as the 
commonly used data sets consist of many thousands, even millions of 
compounds. As virtual screening is a relatively new field of science, there is a 
need for novel methods and for the improvement of existing virtual screening 
protocols. In this thesis, a novel ligand-based virtual screening method called 
FieldChopper was developed. FieldChopper can be used when multiple, 
similarly binding active compounds are known. This novel method 
outperformed techniques based on single ligand similarities in a comparative 
study. In addition, the effects of tautomerism and protonation in structure-
based virtual screening were studied with large data sets. It does appear that 
current methods are not yet accurate enough for separating between different 
tautomers and protonation sets and therefore the use of multiple forms of 
molecules in structure-based virtual screening is simply a waste of resources. 
The effect of conformational analysis approaches on ligand-based virtual 
screening using shape-based overlay techniques was investigated. It was 
shown that with GPU computing and single conformation databases that even 
large databases can be screened on a regular desktop computer. 
 
National Library of Medicine Classification: QU 34, QV 26.5, QV 744 
Medical Subject Headings: Drug Discovery; Models, Molecular; Molecular 
Structure; Molecular Conformation; Ligands; Computer-Aided Design; 
Software; Software Design 
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Kalliokoski, Tuomo. Kolmiuloitteisen virtuaaliseulonnan nopeuttaminen: 
uusia ohjelmia ja lähestymistapoja tietokoneavusteiseen 
lääkeainesuunnitteluun. Itä-Suomen yliopiston julkaisuja. Terveystieteiden 
tiedekunnan väitöskirjat, 22. 2010. 174 p. 
TIIVISTELMÄ 
Virtuaaliseulonnalla tarkoitetaan yhdisteiden pisteyttämistä halutun 
ominaisuuden suhteen tietokoneen avulla. Yleensä ennustetaan yhdisteen 
biologista aktiivisuutta in vitro -kokeessa perustuen joko vertaamalla 
samankaltaisuutta tunnettuihin aktiivisiin yhdisteisiin (ns. ligandi-pohjainen 
virtuaaliseulonta) tai kohdeproteiiniin rakenteeseen telakoimalla (ns. rakenne-
pohjainen virtuaaliseulonta). 
Kolmi-ulotteisessa virtuaaliseulonnassa sekä pieniä molekyylejä että 
proteiineja käsitellään joustavina kolmiulotteisina rakenteina. Tämä lisää 
seulonnan laskennallista vaativuutta huomattavasti. Koska käsiteltäviä 
molekyylejä on yleensä tuhansia ja aikataulut lääkekehitysprojekteissa 
tiukkoja, on virtuaaliseulontamenetelmien oltava nopeita. 
Tässä väitöskirjatyössä kehitettiin uusi ligandi-pohjainen nopea 
virtuaaliseulontamenetelmä FieldChopper, jota voidaan käyttää, kun 
tunnetaan useita samaan sitoutumistaskuun vaikuttavia yhdisteitä. Alustavien 
tulosten mukaan FieldChopper voi olla hyödyllinen molekyyliseula. 
Uusia lähestymistapoja kehitettiin sekä rakenne- että ligandi-pohjaiseen 
virtuaaliselontaan. Ligandien tautomerian ja erilaisten protonaatiomuotojen 
vaikutusta molekyylitelakointiin on arvioitu aikaisemmin suureksi. Tässä 
tutkimuksessa havaittiin, että nykyisillä telakointiohjelmilla erot ovat luultua 
pienempiä ja seulontaprosessia voidaan yksinkertaistaa lisänopeuden 
saamiseksi. Viimeisessä osatyössä selvitettiin konformaatioanalyysin 
vaikutusta muotoon perustuvassa, ligandi-pohjaisessa virtuaaliseulonnassa. 
Yleisimmin käytetty menetelmä, jossa hakumolekyyliä käsitellään jäykkänä 
rakenteena ja tietokantamolekyylejä joustavina, ei tulosten mukaan ole 
välttämättä optimaalinen ratkaisu. 
 
Yleinen suomalainen asiasanasto: lääkkeet; lääkeaineet; molekyylit; rakenne; 
kolmiulotteisuus; tietokoneavusteinen suunnittelu; ohjelmistokehitys 
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Quantity has a quality all of its own.  
A remark usually attributed to Joseph Stalin (1878-1953) 
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1 Introduction 
Drug discovery and development is a long and expensive 
process, taking on average 12-15 years and costing 0.8-1.7 billion 
US dollars (DiMasi et al. 2003; Adams and Brantner 2006; Paul et 
al. 2010). The process is illustrated with a simplified flowchart 
on Figure 1.1. Initially, there must be a disease or symptom for 
which there is need for a novel drug. Since the drug 
development is so expensive, financial aspects must be also 
considered.  
The first step in the actual development process is the drug 
target identification and validation. Novel drug targets are often 
identified via basic research by analyzing various molecular 
pathways. After a potential drug target has been identified, a 
cell-based assay needs to be developed in order to measure the 
biological activity of chemicals for the target. 
Large chemical libraries have been created with combinatorial 
chemistry techniques. Natural sources like plants and bacteria 
provide also useful sources for drug molecules. The chemical 
libraries are evaluated for the drug target in a process called 
High-Throughput Screening (HTS), which is conducted by 
robots. An alternative to this rather laborious and expensive 
HTS method is to use computers for the prediction of biological 
activity (virtual HTS).  
When a biologically active compound is identified from the 
initial screening, it is then tested in more sophisticated assays 
and thus selected as a lead molecule for the drug development 
process. The lead molecule is modified into a drug candidate by 
improving its pharmacokinetic and pharmacodynamic 
properties by synthesizing numerous analogues of the main 
compound. After animal testing, the molecule is tested on 
human volunteers. The most expensive parts in the drug 
development are the clinical experiments that demonstrate the 
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efficacy of the new drug molecule. Finally, drug must pass 
through a rigorous regulatory procedure before it can reach the 
market. 
In addition to being an extremely expensive and long process, 
development of a new drug molecule is also risky as about nine 
out of ten candidate molecules fail to complete the course before 
they are accepted as drugs (Shah and Federoff 2009). The extra 
money spent in research and development has not increased the 
number of new chemical entities entering the market (Tralau-
Stewart et al. 2009). Therefore, novel and preferably cheap 
methods are urgently needed by the pharmaceutical industry in 
order to boost its productivity (Paul et al. 2010). Computer-
based methods are one such strategy. As the selection of a 
reasonable lead structure is a critical step for the successful 
development of a drug, the lead identification step has received 
considerable attention recently (Köppen 2009; Paul et al. 2010). 
International Union of Pure and Applied Chemistry (IUPAC) 
have defined virtual screening (also called in silico screening) as 
the “selection of compounds by evaluating their desirability in a 
computational model” (Maclean et al. 1999). In this thesis, it is 
assumed that the number of compounds screened will be large, 
from thousands to millions of molecules (virtual high-
throughput screening). The focus of this study has been in the 
development of novel rapid virtual screening software and the 
acceleration of current methods. 
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Figure 1.1: The drug development process (O'Driscoll 2004) 
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2 3D-Virtual Screening 
Most drug molecules act via interactions with the various target 
proteins that exist in the organism, e.g. receptors, ion-channels, 
enzymes and transport proteins. In modern drug discovery, 
these targets are typically identified by the genetic analysis of 
the molecular pathways involved in a disease state (Zhu and 
Cuozzo 2009).  
A compound that binds to a protein is called a ligand (Nelson 
and Cox 2005). It binds to the active site of the protein, which is 
complementary to the ligand in its steric and electrostatic 
properties. The specific nature of the binding can be compared 
to a key (ligand) and lock (protein), the model first proposed in 
the end of 19th century (Fischer 1894). The model is illustrated 
in Figure 2.1. It shows protein P, which has a triangular-shaped 
active site. The ligand A is a triangle, so it fits the active site and 
thus is able to bind to the protein. However, inactive compound 
B is a circle, so it will not fit. 
 
TARGET PROTEIN
PActive Site
A
LIGAND
B
INACTIVE COMPOUND
 
Figure 2.1: The Fischer’s key and lock model. Ligand A fits the active site of target 
protein P, whereas inactive compound B does not. 
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Fischer’s key and lock model is however overly simplistic, as it 
implies that ligands and proteins are rigid objects. The binding 
of a protein and ligand often induces a change in the binding 
site, which is called ”induced fit” (Koshland 1958; Koshland 
1996). Both the ligand and target protein adapt their 
conformation for better complementary (Jorgensen 1991; Nelson 
and Cox 2005). The induced fit theory is illustrated in Figure 2.2. 
At first, ligand C does not match the active site of protein P, but 
after undergoing induced fit, it is able to bind. There a better 
metaphor for the protein-ligand process is a hand (ligand) and 
glove (protein) instead of the rigid objects like a key and lock 
(Rao 2005). 
 
PGC PGC
 
Figure 2.2: The Koshland induced fit theory. The ligand C induces a change in protein 
P’s conformation, which makes the binding site more complementary to the ligand. 
 
The induced fit theory does not explain all observed phenomena 
relating to the protein-ligand binding and recently a theory 
called “conformational selection” has emerged (Bosshard 2001; 
Boehr et al. 2009). It is illustrated on Figure 2.3 as a 
thermodynamic circle. Protein P can exist in two conformations 
in solution (P1 and P2). The binding conformation P2 pre-exists 
in solution before the ligand D is added. The kinetic constants 
K1 and K2 define, in addition to thermodynamic factors, if the 
binding of ligand D is via induced fit or conformational 
selection. 
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D
P2
D
P1P1
D
P2
D
K1
K2
Conformational
changePre-equilibrium
Conformational
selection
Induced
fit
 
Figure 2.3: Conformational selection theory (adapted from Boehr 2009). The process 
can viewed as a simplified thermodynamic cycle. 
 
In virtual screening, often the simplest Fischer theory of a rigid 
protein is considered due to computational demands (McInnes 
2007). However, it has been recommended to be cautious and 
keeping the complexity of the biomolecular recognition process 
in mind in order not to over-interpret results from VS studies 
(Bissantz et al. 2010). 
The overall view of the virtual screening process is shown in 
Figure 2.4. Virtual screening can be divided into two major 
strategies: ligand-based virtual screening (LBVS) and structure-
based or target-based virtual screening (SBVS) (Rester 2008). 
Both approaches can be applied simultaneously provided that 
enough information is available. As with any modeling 
procedure, experimental data is required before predictions can 
be made. In LBVS, the information about other similarly 
bioactive compounds (“keys”) is used, whereas in SBVS 3D-
models of the target proteins (“locks”) are utilized. The 3D-
models of target proteins are either derived from X-ray 
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crystallography and Nuclear Magnetic Resonance (NMR) 
experiments or homology modeling, where the existing 
experimental data is used to build comparative models of 
proteins from their amino acid sequence. The chemical libraries 
that are screened are usually created using combinatorial 
chemistry techniques or they are built from natural products, 
such as chemicals extracted from plants. The result of a virtual 
screen is a hit list that is a prioritized list of compounds suitable 
for biological testing (in vitro evaluation). It is hoped that the top 
of the hit list contains more bioactive compounds than could be 
obtained from a random selection. 
 
Quick
filtering
Scoring
Hit list
In vitro
evaluation
Homology
modelling
Database
preparation
Structure-Based
Virtual Screening
(SBVS)
Ligand-Based
Virtual Screening
(LBVS)
X-ray/
NMR Sequence
Natural
products
Combinatorial
chemistry
Biologically
active
compound(s)
Protein
model
Query
molecule(s) Database
DockingSimilaritysearching
 
Figure 2.4: Overview of virtual screening 
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Virtual screening has many attractive qualities. The number of 
compounds that can be screened is much larger than with 
biological screening (Figure 2.5). In an academic setting, usually 
only virtual screening is possible due to the high costs related to 
HTS. The size of medicinal chemistry space is almost infinite, 
estimated to be 1060 molecules (Nicholls 2008; Köppen 2009). 
This is truly a staggering number: for comparison NASA Glenn 
Research Center has estimated that the total mass of all the stars 
in the observable universe is 3 * 1052 kg (NASA 2009). In a 
typical academic virtual screening study, one to ten million 
compounds will be screened for their biological potential and 
approximately 100-1000 molecules are tested in vitro. The large 
number of compounds to be screened means that virtual 
screening methods need to be fast in order to be truly useful for 
drug development. 
As the price of high-performance computing has plummeted 
due to advances in both hardware and software, virtual 
screening costs only a small fraction of HTS. One can also 
predict bioactivity for molecules that can be readily made, but 
do not yet exist (virtual libraries). This strategy is often applied 
in the lead optimization phase. 
 
 
Figure 2.5: The numbers of molecules available from different sources (Köppen 2009). 
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Next, an overview for LBVS- and SBVS-methods is given with 
short introductions to high-performance computing (HPC) and 
database preparation. It should be noted that as there are 
thousands of different methods proposed in the literature 
(Todeschini and Consonni 2009); only some of the most used 
publicly available techniques are discussed. As the experimental 
part of this thesis is based on the acceleration of 3D-based 
virtual screening methods, the 2D-methods are only briefly 
mentioned. The different methods are viewed from 
practitioner’s view and not discussed in algorithmic detail. This 
literature review hopes to consider most of the readily available 
3D-virtual screening tools available on May 2010. 
2.1 HIGH-PERFORMANCE COMPUTING IN VIRTUAL 
SCREENING 
Since a large amount of data is processed in virtual screening, 
High-Performance Computing (HPC) is required for most real-
life applications. HPC is based on massively parallel computing 
using supercomputers and computer clusters. Most algorithms 
used in virtual screening are trivial to parallelize by splitting the 
data into smaller pieces. 
In the past, HPC required specialized and expensive hardware. 
Due to the availability of cheap multicore processors and free 
operating systems like Linux, this is no longer the case. Even a 
single person can build and maintain an HPC system with a 
small budget. The 56-CPU cluster located in University of 
Eastern Finland is an example of such a computer. It was built 
by the author without previous knowledge about how to set up 
such a system and it was ready for production in less than a 
month. 
Recently, the power of graphical processing units (GPUs) has 
become readily available for scientific computing via general-
purpose computing on graphics processing units (GPGPU). 
Originally developed for 3D graphics, the modern GPUs can 
perform parallel general-purpose calculations extremely fast 
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compared to regular CPUs. In addition to having high-
performance, GPU hardware is also cheap and readily available 
as it is used for computer gaming. The downside of GPUs is that 
they are difficult to program and achieving high performance 
requires a thorough understanding of hardware details. 
However, the hard work pays off. The higher throughput 
combined with the cheap price of GPU-hardware allows the 
screening of extremely large databases with regular desktop 
computers instead of supercomputers (Giupponi et al. 2008). 
2.2 LIGAND-BASED VIRTUAL SCREENING (LBVS) 
Ligand-based virtual screening is based on “the similarity 
principle” that states that similar molecules tend to have similar 
biological properties (Eckert and Bajorath 2007). Molecular 
similarity is a subjective concept like beauty and molecules can 
be “similar” in many different ways (Maggiora and 
Shanmugasundaram 2004; Sheridan and Kearsley 2002). 
Although the term “ligand-based virtual screening” has only 
recently appeared in the literature, the idea is not new (Bohm et 
al. 2004). For instance, bioisosteric modifications are small 
modifications to molecules that are based on rules like 
"hydrogen can be changed to fluorine without losing the 
biological activity" (Patani and LaVoie 1996). 
The aim of LBVS is usually scaffold hopping. LBVS methods can 
be also helpful in drug repurposing, where new targets and 
diseases are sought for existing drug molecules (Ashburn and 
Thor 2004). Scaffold hopping can be defined as the identification 
of isofunctional molecular structures with significantly different 
molecular backbones (Schneider et al. 1999). Although "scaffold 
hopping" is the most commonly used term (Fitzgerald et al. 
2007), "leapfrogging" (Stanton et al. 1999), "scaffold searching" 
(Hert et al. 2006) and "lead hopping" (Cramer et al. 2004) have 
also been used to describe this strategy.  
Some examples of different motivations and successes of 
scaffold hopping are presented in Table 2.1. Since peptides make 
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very poor drug molecules for various reasons (e.g. flexibility, 
proteolytic stability), it is desirable to replace the peptidic 
scaffold of a bioactive molecule (Bohm et al. 2004). Several 
successful cases have been published where peptides have been 
substituted by other structures (Ripka and Rich 1998).  
Poor absorption, distribution, metabolism, excretion and toxicity 
(ADMET) properties may also be the reasons for scaffold 
hopping (Rush et al. 2005). If a lipophilic scaffold can be 
changed to a more polar one, this will increase the solubility of 
the compound, which is often a major problem in contemporary 
drug discovery programs (Lipinski 2000; Paul et al. 2010).  
Scaffold hopping has also been used for intellectual property 
issues. When a “breakthrough-drug” is introduced onto the 
market by a pharmaceutical company, its competitors try to 
develop molecules with similar biological but a dissimilar 
chemical structure (“me-too” drugs). 
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Table 2.1: Some examples of different motivations and successes of scaffold hopping 
Target Issues with original ligand Reference 
Histamine H3 
Chemical/metabolic instability, 
hERG-channel inhibition 
Lau et al. 2006 
Activator protein-1 (AP-1) Peptide 
Tsuchida et al. 
2006 
HIV TAR RNA 
Pharmacokinetics (multiple 
charges, size) 
Renner et al. 
2005 
Cholecystokinin-2 (CCK2) 
High levels of biliary 
elimination 
Low et al. 2005 
HIV-1 reverse 
transcriptase 
Metabolic instability 
O’Meara et al. 
2007 
Sphingosine 1-phosphate-
3 Receptor (S1P3) 
Potency and selectivity Koide et al. 2007 
Glycogen Synthase 
Kinase-3 (GSK-3) 
Not suitable for further 
optimization 
Naerum et al. 
2002 
5-lipoxygenase (5-LO) Lack of selectivity 
Franke et al. 
2007 
Tau protein aggregation Toxicity, cell penetration Larbig et al. 2007 
Histamine H4 Very short half-life Smits et al. 2008 
Glutamate racemase 
(Murl) 
Restricted antibacterial 
spectrum 
Breault et al. 
2008 
Trypanothione Reductase Potency and selectivity 
Perez-Pineiro et 
al. 2009 
Kinases Undesirable thiourea linker Tasler et al. 2009 
 
Even though popular, scaffold hopping is an ill-defined term 
and highly subjective concept (Brown and Jacoby 2006; Bohm et 
al. 2004). There are various definitions for a scaffold (Roberts et 
al. 2000; Xu 2002; Jenkins et al. 2004; Krier et al. 2006; Barker et 
al. 2006; Wilkens et al. 2005). One of the first definitions of 
scaffold was made in a patent by Markush (Markush 1924; 
Brown and Jacoby 2006). It defined a set of dye 
chemicals:”…dyes which comprises coupling with a halogen-
substituted pyrazolone, a diazotized unsulphonated material selected 
from the group consisting of aniline, homologues of aniline and 
halogen substitution products of aniline”. Markush structures are 
used by drug companies to protect chemical series around a 
promising molecule, even though not all of the structures are 
even possible to synthesize, let alone having any biological 
13 
 
  
 
effect whatsoever. Therefore, Markush structures are more of a 
legal tool than a scientific concept (Brown and Jacoby 2006).  
The most commonly used scaffold concept is based on the work 
of Bemis and Murcko, where they analyzed the properties of 
known drugs using the Comprehensive Medicinal Chemistry 
(CMC) database (Bemis and Murcko 1996). These scaffolds are 
sometimes referred to as “Murcko’s scaffolds” or “molecular 
frameworks” (Krier et al. 2006; Lipkus et al. 2008). The 
classification is based on a hierarchical description of molecules, 
illustrated in Figures 2.6 and 2.7. A molecule consists of a 
scaffold that has side chains, whereas a scaffold consists of a 
ring system and linkers. Murcko’s scaffolds have the obvious 
pitfall that only cyclic scaffolds that were included in the CMC 
datasets can be detected. Recently, Lipkus and co-workers 
analyzed the scaffolds found in the CAS registry using a similar 
approach to Bemis and Murcko. They found out that half of the 
24 million organic compounds in CAS could be described by 
only 143 scaffolds. Other general classifications are the 
maximum common substructures (McGregor and Willett 1981), 
maximum rigid fragments (Su et al. 2001) and RECAP 
fragments (Lewell et al. 1998). The problem of scaffold definition 
has not yet been satisfactorily solved and it will be discussed 
also in Chapter 3.3. 
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Molecule
Sidechain Scaffold
Ring system Linker
 
Figure 2.6: Hierarchical description of molecules (adapted and modified from Bemis 
and Murcko 1996). 
 
Scaffold
Ring
systems
Sidechain
Linker
 
Figure 2.7: Detecting scaffolds using concepts of ring systems, linkers and side chains 
(adapted and modified from Bemis and Murcko 1996). 
 
One example scaffold hopping is shown in Figure 2.8, where 
there are the two similarly bioactive compounds that have 
completely different scaffolds. Hypothesis for their similar 
activity is based on matching three-dimensional shape of the 
molecules. 
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Figure 2.8: Example of scaffold hopping. NAADP and NED-19 have similar 
bioactivity even though their scaffolds are completely different. Both molecules are 
similar in their 3D surfaces (black and white shapes) (Connolly 1983). Analysis is 
based on the findings of Naylor and co-workers (Naylor et al. 2009). 
 
There are many similarity methods which have been developed 
for LBVS. Some of the commonly used approaches are 
presented in Table 2.2. For a comprehensive listing, the 
interested reader is referred to the recent book of Todeschini 
and Consonni (Todeschini and Consonni 2009). 
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Table 2.2: Some of the commonly used LBVS approaches (Eckert and Bajorath 2007; 
Poptodorov et al. 2006; Rester 2008) 
Method Example(s) Approach 
0D/1D descriptors Atom counts 
Generated from 
molecular graph 
2D fingerprints MACCS 
Quantitative 
comparison of bit 
strings 
3D descriptors 
UNITY3D, NPR, USR, 
ESshape3D, GRIND 
Generated using 
intramolecular 
distances 
Pharmacophores Catalyst 
Common 
features of active 
molecules are 
detected 
3D similarity based on 
pair-wise alignment 
ROCS/EON, BRUTUS, ShaEP, 
FlexS 
Comparison of 
superimposed 
molecules 
2.2.1 0D-2D descriptors 
 
The simplest ways of describing molecules are the one- and two-
dimensional descriptors like the number of carbon atoms or 
molecular indexes based on graph theory (Hall and Kier 1991). 
These kinds of descriptors are easy to calculate with modeling 
tools like MOE (Chemical Computing Group). Despite their 
simplicity, they have been shown to be surprisingly effective in 
virtual screening. For example, in the study of Bender and Glen, 
a large data set of over 100000 compounds containing 11 activity 
classes was screened using the number of atoms per chemical 
element as a molecular descriptor (Bender and Glen 2005). 
Enrichment factors over random selection of around four were 
achieved and also diverse chemical scaffolds were detected in 
the active group. 
The commonly used two-dimensional fingerprints are binary 
strings that encode the presence or absence of sub-structural 
fragments (Willett 2006). A set of chemical features is defined 
and then a bit is set to either zero (0) or one (1), depending on 
whether the substructure exists in the molecule or not. A 
fingerprint is a long bit string, which can also be expressed as an 
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integer. An example of a two-dimensional fingerprint is shown 
in Figure 2.9, which illustrates the MACCS-fingerprint for 
citalopram. 
 
F
O
N
N
citalopram
Bit 41: Carbon triple-bonded to nitrogen
Bit 156: Three bonds that end to nitrogen
Bit 161: Nitrogen
Bit 134: Halogen
Bit 162: Aromatic
Bit 165: Ring
Bit 74: Atom with two methyl groups
Bit 107: Three to four atoms long chain
Bit 158: Nitrogen single-bonded to carbon
00000001001000000000000000000000000000001100000000000000100001000100000001000000000
01010000010010001000000111011001101000100000110010100110001010011110110111101110110
40543750217144624702731259057311301010142489740416
BINARY FORM
INTEGER
 
Figure 2.9:  Example of 2D fingerprint: MACCS structural keys for citalopram. For 
clarity, only some of the defined bits are shown. Fingerprint generated with OpenBabel 
2.2.3 (Guha et al. 2006). 
 
There are many 2D fingerprint methods available but it is 
scientifically difficult to accept any 2D fingerprint as a golden 
standard (Eckert and Bajorath 2007). The most commonly used 
fingerprints are UNITY from Tripos Inc (for example, 
Schuffenhauer et al. 2000; Raymond and Willett 2002; Holliday 
et al. 2003), MACCS/MDL Keys from MDL (for example, 
Koehler et al. 1999; Wild and Blankley 2000; Durant et al. 2002) 
and Daylight from Daylight Chemical Information Systems (for 
example, Kogej et al. 2006; Capelli et al. 2006; Stiefl and Zaliani 
2006). 
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Usually a single fingerprint is compared with a database in 
order to retrieve similar compounds. However, it is also possible 
to form fusion fingerprints based on multiple fingerprints from 
several query molecules (Willett 2006). 
There are numerous similarity coefficients for measuring the 
similarity between two 2D fingerprints (Todeschini and 
Consonni 2009). For example, Holliday and co-workers have 
compared 22 different coefficients with UNITY fingerprints 
(Holliday et al. 2003). The most widely used similarity 
coefficient was formulated by Tanimoto in 1957 (Willett et al. 
1998): 
 
௖ܶ ൌ
ܿ
ܽ ൅ ܾ െ ܿ
 
 
where a is the number of bits set to one in the first fingerprint, b 
is the number of bits set to one in the second fingerprint and c is 
the number of bits set at identical positions in both fingerprints. 
The Tanimoto coefficient is between 0 (completely different) and 
1 (completely similar). 
There has been much debate on the approriate value for the 
Tanimoto coefficient in similarity searching with some workers 
attempting to use a fixed threshold (0.85) for all screens 
(Patterson et al. 1996; Matter 1997). However, this has been 
proven to be an inefficient approach (Martin et al. 2002). It 
seems that compound class specific effects strongly affect 
fingerprint calculations and proper thresholds have to be set on 
a case-by-case basis (Godden et al. 2005). 
Even though 2D fingerprints have proved to be useful tools in 
drug discovery projects, they suffer from several drawbacks 
(Raymond and Willett 2002). For example, a single atom change 
in a ring structure may change the fingerprint from being nearly 
similar to almost completely different. Moreover, as is shown in 
Figure 2.8, two compounds that have very different topologies 
can nonetheless adopt a similar orientation and thus could have 
similar biological effects. Since this thesis is about 3D-virtual 
screening, the reader interested in 2D methods is referred to a 
comprehensive review on the subject (Willett 2006). 
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2.2.2 3D descriptors 
3D fingerprints (also known as pharmacophore keys) encode 3D 
relationships in a molecule as a bit string (Matter 1997; Good et 
al. 2004a; Leach 2001). An example of such an algorithm is the 
UNITY 3D fingerprints (Tripos 2009). The basic idea is 
presented in Figure 2.10, where there are two different 
conformations of disulfiram. The combinations of features are 
enumerated with the distances between them. In a 3D-
fingerprint, each bit encodes a distance between specific groups. 
For example, bit 0 could be ”donor-donor with distance 2-2.5” 
and bit 1 ”donor-donor with distance 2.5-3” etc. The number of 
features used in combinations varies from two up to nine 
(Martin and Hoeffel 2000). However, the size of a fingerprint 
increases rapidly with the number of features used. 
 
 
Figure 2.10: Two conformations of disulfiram. The three-point pharmacophoric feature 
is different in the two conformations. Conformations generated with OPLS_2005 force 
field implemented in MacroModel (Schrödinger Inc). Image created with Maestro 
(Schrödinger Inc). 
 
The basic problem with 3D fingerprints (and with other 3D 
methods as well) is of course conformational sampling, since the 
number of possible conformations N increases very rapidly with 
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the number of rotating bonds n (so called combinatorial 
explosion)  (Kitchen et al. 2004; Boström and Grant 2008): 
 
ܰ ൌ ൬
͵͸Ͳ
݉
൰
௡
 
 
where m is the size of the rotational angle in degrees. For 
example, a molecule with six rotatable bonds has 2985984 
possible conformations with a rotational angle increment of 30 
degrees. It is therefore not possible to use all possible 
conformations in similarity calculations for most molecules. The 
problem of conformational analysis will be discussed more in 
Chapter 2.5.3. 
Shape-based descriptors encode the shape of the molecule into 
numbers. The shape complementarness of the ligand to the 
active site is a prerequisite for the drug action, so several 
approaches for describing this important feature have been 
developed (Putta and Beroza 2007). If compared to the 3D 
fingerprints, which describe molecules as sets of atoms, the 
shape-based descriptors consider molecules as volumes and 
surfaces (Nicholls et al. 2010). The normalized ratio of principal 
moments of inertia (PMI) is an example of a shape-based 
descriptor (Sauer and Schwarz 2003). PMIs are easily calculated 
with molecular modeling packages like SYBYL and they have 
been widely used to assess molecular shape, geometry and 
conformation. Three principal components are calculated and 
assigned by ascending order to I1, I2 and I3. These are normalized 
by dividing the lower values I1 and I2 by I3. The normalization 
eliminates the dependency on the size of the molecules. These 
normalized PMI ratios (NPRs) fulfill the following relation due 
to the intrinsic characteristic of the inertia tensor: 
 
ܫଶ
ܫଷ
൒ ሺ
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Therefore, the resulting plot against each other is an isosceles 
triangle onto which all molecules can be placed. The three 
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corners correspond to archetype shapes of spheres, disks and 
rods (Figure 2.11). Compounds are mapped to different parts of 
the triangle according to their shape. 
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Figure 2.11: Some examples of normalized PMI ratios and corresponding structures 
(adapted from Sauer and Schwarz 2003). Conformations were calculated with 
CORINA (Molecular Networks GmBH) and NPRs were calculated with MOE 
(Chemical Computing Group). Molecules were visualized with Maestro (Schrödinger 
Inc) 
 
However, this methodology has obvious serious flaws. For 
example, completely different molecules like methane and 
fullerene would be classified as similar because they adopt a 
similar sphere-like conformation. 
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The shape-based descriptors that are more relevant to the virtual 
screening are ESShape3D (implemented in MOE by Chemical 
Computing Group) and Ultrafast Shape Recognition (USR). 
ESshape3D is formed by first measuring the Euclidean distance 
between all pairs of the heavy atoms in the molecule (Henry A, 
personal communication, Jan 12th, 2010; Ballester et al. 2009). 
Then, the eigenvalues are calculated from this distance matrix. 
The signed square roots of these eigenvalues are smoothened 
with a Gaussian function and stored in a histogram with 122 
bins containing values between -30 and 30. The similarity 
between two ESshape3D descriptors is calculated from the 
distance between the values for each of the histogram bins. For 
example, if we assume that there are two molecules with 
distances A and B (three bins instead of the 122 used for clarity): 
 
ܣ ൌ ሾͳͲǡʹͲǡ͵Ͳሿ 
ܤ ൌ ሾ͵ͲǡʹͲǡͳͲሿ 
 
The difference between A and B would be [-20, 0, 20]. The 
distance D is the square root of the sum of the squared 
differences (√800). The similarity S is calculated from the 
distance D (S=0.714): 
 
ܵ ൌ
ʹ
ʹ ൅ ܦͳͲͲͲ
 
 
USR is based on atomic intramolecular distances from four 
molecular locations that are used to form a 12 element vector 
(Ballester and Richards 2007a; Ballester and Richards 2007b). It 
is one order of magnitude faster to calculate than the 
ESShape3D descriptor (Ballester et al. 2009). The similarity 
between two descriptors A and B is calculated from: 
 
ܵ ൌ
ͳ
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USR is implemented in Chemical Development Kit (CDK) by 
Guha (DistanceMoment class). A command line user interface 
was written by the author to conduct a virtual screening and to 
calculate descriptors with USR (available via 
http://www.uku.fi/~tkalliok/usr). 
Since both steric and electrostatic properties are important in 
protein-ligand complementary, the accuracy of shape-based 
descriptors for virtual screening is limited (Nicholls et al. 2010). 
Examples of a descriptor that encodes both shape and 
electrostatic properties are Grid-Independent descriptors 
(GRIND) (Pastor et al. 2000). The descriptors are derived from a 
collection of GRID molecular interaction fields computed using 
different chemical probes based on the work of Goodford 
(Goodford 1985). These fields are then discretized by finding 
“the hot spots” of interactions. The relative position of “hot 
spots” is then encoded into descriptors called correlograms. 
Principal component analysis of the correlograms is then used 
for the similarity calculations. The algorithm for the calculation 
of GRIND descriptors has evolved over the years (Fontaine et al. 
2004; Durán et al. 2008; Durán et al. 2009). The most recent 
version of the method is implemented in Pentacle (available 
from Molecular Discovery Ltd). 
2.2.3 Pharmacophores 
The term pharmacophore was introduced by Paul Ehrlich in 
1909 (Ehrlich 1909; Triballeau et al. 2006). The modern IUPAC 
definition dates from 1998: "A pharmacophore is the ensemble of 
steric and electronic features that is necessary to ensure the optimal 
supramolecular interactions with a specific biological target structure 
and to trigger (or to block) its biological response." (Wermuth et al. 
1998) 
A pharmacophore is an abstract concept that describes the 
interaction capability of either one or a group of compounds 
toward a drug target instead of a real molecule or real 
association of functional groups (Wermuth 2006). 
Pharmacophores can be also constructed from protein models 
(Wolber and Langer 2005). The main advantage of 
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pharmacophore methods is that it is possible to find very 
diverse compounds. The early pharmacophores were 
constructed manually in the 1940’s with the knowledge of the 
bond lengths and the van der Waals radii of atoms (Figure 2.12). 
Such simple constraints could be used as a crude filtering 
criterion for large set of compounds to weed out clearly 
unsuitable molecules. 
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Figure 2.12: Two early pharmacophores with example molecules (adapted from 
Wermuth 2006) 
 
The pioneers in the modern computational pharmacophore 
identification are Marshall and co-workers who developed the 
so-called Active Analog Approach in the 1970’s (Marshall et al. 
1979). The core algorithm is illustrated in Figure 2.13. The 
number of conformations for a flexible molecule is reduced by 
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the geometry of a rigid reference molecule. Pharmacophores are 
then derived from these alignments. This approach forms the 
basis of many existing automated pharmacophore generation 
methods (van Drie 2004; Poptodorov et al. 2006). 
 
Molecule #2 Molecule #3
Molecule #1
X
 
Figure 2.13: The Active Analogue approach by Marshall and co-workers (adapted from 
van Drie 2004). The circles represent the available conformational space. The 
intersection X is the area from which the common pharmacophores will be found. 
 
The work flow for general pharmacophore modeling is 
presented in Figure 2.14. Several compounds that have similar 
biological activities are needed to form a hypothesis. Some 
methods also allow incorporation of activity data. An important 
assumption is that all compounds in the pharmacophore have a 
similar binding mode and thus they can be superimposed. After 
compounds are superimposed, common features of the 
molecules can be detected. A pharmacophore can almost always 
be generated, but it must be validated by using an external data 
set before use. After a reasonable pharmacophore is formed, the 
virtual screening step itself is fast. 
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Figure 2.14: General pharmacophore modeling workflow (adapted and modified from 
Poptodorov et al. 2006) 
 
To some extent, pharmacophores have been neglected and the 
development of new methods has been extremely slow (Langer 
and Hoffmann 2006). This might be due to the strong emphasis 
on SBVS in recent years. Since SBVS methods have not been as 
successful as was originally anticipated, there has been 
increasing interest in using the pharmacophore approach (Kolb 
et al. 2009; Leach et al. 2010). 
Geometry- and feature-based pharmacophore methods usually 
consider compounds as sets of connected features like 
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hydrophobic and H-bond acceptors/donors (Poptodorov et al. 
2006). These features are important for selective binding of drug 
molecules as they describe hydrogen bonding, electrostatics and 
hydrophobic interactions. As a practical example of these kinds 
of chemical function definitions, Greene et al. (1994) proposed a 
set of features based on atom types (Figure 2.15). A similar set is 
used in most modern pharmacophore programs. This set, 
originally implemented in Catalyst software, is not completely 
satisfactory, as for example it will describe incorrectly both 
oxygen atoms in esters as “hydrogen bond acceptors”. 
 
 
Figure 2.15: Pharmacophore features as proposed by Greene et al. (1994). 
 
The most widely used geometry- and feature-based 
pharmacophore elucidation method is Catalyst from Accelrys, 
which is currently a part of the Discovery Studio package (some 
recent applications of the methodology are presented in Table 
2.3). Catalyst is an integrated set of algorithms for conformation 
generation (ConFirm), molecular superimposition (HipHop), 
pharmacophore generation (HypoGen) and database searching 
(Info). HipHop and HypoGen provide two approaches for 
automatic pharmacophore generation. HipHop identifies 
pharmacophores by aligning the chemical features of active 
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molecules (Barnum et al. 1996). Each conformation of each 
molecule is used as a reference for alignment and every 
configuration is scored. HypoGen is designed to correlate 
structure and activity for automatic pharmacophore generation 
(Poptodorov et al. 2006), working in three steps. In the first step, 
common features are detected between the two most active 
compounds. In the second step, those features that are common 
between active and inactive compounds are removed from the 
pharmacophore. The last step is an optimization phase where 
simulated annealing is used to improve the predictive power of 
the pharmacophore. An exclusion volume can be added to 
HypoGen pharmacophores to filter out too large molecules from 
the search. For a more detailed description of Catalyst and other 
feature-based pharmacophore generation methods, the reader is 
referred to recent review articles (Poptodorov et al. 2006; Leach 
et al. 2010). 
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Table 2.3: Some recent examples of Catalyst-based pharmacophores for virtual 
screening 
Target Reference 
Human adenosine kinase Bhutoria and Ghoshal 2010 
Bovine viral diarrhea virus Tonelli et al. 2010 
11β-hydroxysteroid dehydrogenase 1 
Rollinger et al. 2010; 
Schuster et al. 2006 
Phosphodiesterase type-5 Chen 2010 
Peroxisome proliferator-activated receptor 
gamma 
Fakhrudin et al 2010; Markt 
et al. 2008; Markt et al. 
2007 
5-Lipoxygenase Aparoy et al. 2010 
Human tyrosyl-DNA phosphodiesterase Weidlich et al. 2010 
Plasmodium falciparum dihydrofolate 
reductase 
Adane et al. 2009 
Nuclear factor-kappa B Tsai et al. 2009 
ZAP-70 Sanam et al. 2009 
Transforming growth factor-β Type I 
Receptor (ALK5) 
Ren et al. 2009 
Caspase-3 Laksmi et al. 2009 
Various cancer cell lines Chiang et al. 2009 
Aromatase Neves et al. 2009 
Monoamine Oxidase B Boppana et al. 2009 
Spleen tyrosine kinase Xie et al. 2009 
Aurora B kinase Wang et al. 2009 
Cannabinoid receptor 2 Markt et al. 2009 
Raf-1 kinase Li et al. 2009 
Glycogen Synthase Kinase 3beta Vadivelan et al. 2009 
 
3D-Quantitative Structure Activity Relationships (QSAR) 
methods can be considered as field-based automatic 
pharmacophore generation methods (Poptodorov et al. 2006). 
The most frequently used 3D-QSAR method is Comparative 
Molecular Field Analysis (CoMFA) devised by Cramer and co-
workers (Cramer et al. 1988). Other widely used 3D-QSAR 
methods are CoMSIA (Klebe et al. 1994) and GRID/GOLPE 
(Cruciani and Watson 1994). 
Even though there are hundreds of CoMFA studies published 
(PubMed lists over 900 citations with keyword "CoMFA"), most 
of these studies are mostly retrospective analyses and have very 
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little predictive value that could be used in prospective virtual 
screening of new biologically active molecules (Doweyko 2004). 
Also, the superimposing step is a major limitation for virtual 
screening applications, as the compounds to be screened need to 
have a common scaffold to permit automatic alignment 
(Hillebrecht and Klebe 2008). It could be therefore concluded 
that CoMFA is more a tool for lead optimization rather than a 
virtual screening method for large databases. There is also 
Topomer-CoMFA available, which is easier to use than the 
traditional CoMFA (Cramer 2003). 
CoMFA has however inspired various other field-based virtual 
screening methods, including FieldChopper described in this 
thesis, and it has been used in conjunction with other methods 
to find novel compounds (for an example, see Zhang et al. 2007), 
so it serves as an example of a field-based virtual screening 
method. An outline of the method is presented in Figure 2.16. 
The molecular field is presented as a lattice. Compounds are 
superimposed and their activity values, steric and electrostatic 
potentials are recorded in the QSAR table. From this table, an 
equation is derived with Partial Least Squares (PLS) data 
analysis method (Wold et al. 1984). This equation can then be 
used in the prediction of activity for compounds outside the 
model. Although the basic idea is rather straightforward, the 
correct use of the method is difficult, as the results are critically 
dependent on conformation and superimposition of the 
compounds. Furthermore, the chemical parameters used to 
generate fields and the statistical evaluation methods have a 
large influence on the models. 
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QSAR Table
Compound
C1
C2
Activity
4.2
6.9
Steric 1..N Electrostatic
1..N
P
LS
Activity = y+a*S1+…+m*SN+n*E1+…+z*EN
 
Figure 2.16: Comparative Molecular Field Analysis (CoMFA) (adapted from Cramer 
et al. 1988). 
2.2.4 3D similarity based on pair-wise alignment 
In pharmacophore methods, a set of compounds is compared in 
order to find common features, which are then matched to a set 
of compounds in a database. One can also try to match the 
whole query molecule to database molecules by aligning them 
in a pair-wise manner. It is easier to find a reasonable alignment 
for a pair of molecules than for diverse set of molecules. Some of 
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the recent virtual screening successes using pair-wise alignment 
have been listed on Table 2.4. 
 
Table 2.4: Some recent examples of alignment-based virtual screening 
Target Reference 
ZipA-FtsZ protein-protein interaction Rush et al. 2005 
Biological role of NAADP Naylor et al. 2009 
CB1 receptor Boström et al. 2007 
Metabotropic glutamate receptor 2 Tresadern et al. 2010 
Nipah virus envelope protein Niedermeier et al. 2009 
Melanin Concentrating Hormone Oyarzabal et al. 2009 
Neurotensin NTS1 receptor Fan et al. 2008 
Androgen receptor Trump et al. 2007 
γ-secretase Gundersen et al. 2005 
 
The problem of molecular alignment is a complex issue due to 
the degrees of freedom involved and is comprehensively 
discussed in a recent doctoral dissertation (Rönkkö 2009). From 
a practical point of view, there are several high-throughput 
molecular alignment methods publicly available (Table 2.5). 
 
Table 2.5: High-throughput small molecule alignment-based similarity methods 
suitable for virtual screening. License abbreviations: O=Open Source, F=Free, 
FA=Free for Academic use and C=Commercial. 
Program Reference Lic. Website 
ROCS Grant et al. 1995 FA www.eyesopen.com 
EON Nicholls et al. 2004 FA www.eyesopen.com 
PAPER Haque and Pande 2009 O simtk.org/home/paper 
BRUTUS Rönkkö et al. 2006 C www.visipoint.fi 
ShaEP Vainio et al. 2009 F users.abo.fi/mivainio/shaep 
FlexS Lemmen et al. 1998b C www.biosolveit.de 
 
The most widely used molecular alignment method for virtual 
screening is Rapid Overlay of Chemical Structures (ROCS) from 
OpenEye Scientific Software (Grant et al. 1995; Kirchmair et al. 
2009). In this method, molecules are superimposed with a 
smooth Gaussian function representing the molecular volume. 
ROCS optimizes this function by rigidly translating and rotating 
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the molecule with respect to the query molecule. In the original 
version, optimization started with four initial orientations, but 
the current version has some undisclosed improvements for 
generating the starting positions (Nicholls et al. 2004).  
The similarity S between two molecules A and B is calculated 
from the volumes of the molecules (ShapeTanimoto score): 
 
ܵ ൌ ஺ܱ஻
஺ܱ஺ ൅ ܱ஻஻ െ ஺ܱ஻
 
 
where OAA is the volume of molecule A, OBB is the volume of 
molecule B and OAB is the overlapping volume between these 
molecules. 
In addition to shape, ROCS considers the electrostatic properties 
of molecules via “Color Force Field” (CFF). The CFF is based on 
1D-atom rules that define chemically important areas and has 
rules about how such centers should interact. The hydrogen-
bonding rules are derived from the crystal survey of the 
Cambridge Structural Database (Mills and Dean 1996). Usually, 
the Color Tanimoto value is used in combination with 
ShapeTanimoto (TanimotoCombo). 
EON from OpenEye Scientific Software is a more sophisticated 
electrostatic similarity method (Nicholls et al. 2004). It creates 
electrostatic fields around a pair of aligned molecules and 
calculates the similarity between the two fields. ShapeTanimoto 
is often combined with this electrostatic score. 
Recently an open-source, GPU-accelerated version of ROCS was 
developed called PAPER (Haque and Pande 2009). In addition 
to having the advantage of being free software, PAPER is over 
one order of magnitude faster on a single desktop PC than the 
commercial ROCS package due to the high performance of the 
GPU computing. It does not however have the CFF 
implemented. 
BRUTUS is an automated computer program for rigid-body 
molecular superimposition which considers molecular fields 
(Rönkkö et al. 2006; Rönkkö 2009). It is based on rotating and 
translating molecular fields instead of the molecules. This 
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removes the need to re-calculate the fields during the 
optimization process. In addition, BRUTUS uses a simple 
interpolation algorithm for estimating the energy between grid 
points and this allows the use of coarse energy fields for 
alignment. These factors make BRUTUS fast enough to screen 
large databases. The similarity between the molecular volume 
and electrostatic field is computed separately with the Hodgkin 
index (Hodgkin and Richards 1987). The volumic similarity SV 
and electrostatic similarity Se thus computed are combined to 
the total similarity S: 
 
ܵ ൌ ݓܵ௩ ൅ ሺͳ െ ݓሻܵ௘ 
 
where w is a weighting factor (0.5 is used by default). 
ShaEP is an alignment algorithm based on shape and 
electrostatic potential (Vainio et al. 2009). First, initial 
alignments are produced by a matching algorithm on graphs 
that represent the electrostatic potential of the molecule. Then, 
the alignments are optimized by maximization of the volumic 
overlap using Gaussian functions. It uses a similar total 
similarity score as BRUTUS. 
Incremental construction is implemented in FlexS (Lemmen et 
al. 1998b). Initially, molecules are partitioned into fragments and 
an anchor fragment for the incremental construction procedure 
is either selected by the program or manually by the user. The 
anchor fragment is then placed on the reference ligand and the 
remaining fragments are added iteratively. For virtual 
screening, FlexS uses the RIGFIT algorithm to place the base-
fragment onto the reference molecule (Lemmen et al. 1998a). 
FlexS also uses the Hodgkin index in order to compute the 
similarity between two molecules. 
2.3 STRUCTURE-BASED VIRTUAL SCREENING (SBVS) 
Structure-Based Virtual Screening (SBVS) is usually based on 
molecular docking (Kitchen et al. 2004; Moitessieri et al. 2008). 
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In molecular docking, a small molecule is fitted into the protein 
model’s active site. As an example, oseltamvir was docked into 
N1 neuraminidase with Glide (Figure 2.17). The binding mode 
predicted by docking calculation is remarkably close to the one 
observed in the crystal structure. Several successful virtual 
screening studies have been reported for various proteins (Table 
2.6). 
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Table 2.6: Some recent examples of successful SBVS studies 
Protein Reference 
β2-adrenergic receptor Kolb et al. 2009 
A2A-adenosine receptor Carlsson et al. 2010 
Histamine H4-receptor Kiss et al. 2008 
JAK2 kinase Kiss et al. 2009 
JAK3 kinase Kim et al. 2010 
Ubiquitin C-terminal hydrolase L1 Mitsui et al. 2010 
FGFR1 Ravindranathan et al. 2010 
Death-associated protein kinase 1 Okamoto et al. 2009 
B2 subunit of V-ATPase Ostrov et al. 2009 
Falcipain-2 Li et al. 2009 
Hepatitis C virus nonstructural protein 3 Chen et al. 2009 
Thermolysin Khan et al. 2009 
D-alanine:D-alanine ligase Kovac et al. 2008 
Mycobacterium tuberculosis APSR Cosconati et al. 2008 
SecA ATPase Li et al. 2008 
SRC Lee et al. 2009 
ATP-dependent Mur ligases MurD and MurF Turk et al. 2009 
Sarco/endoplasmic reticulum calcium ATPase Deye et al. 2009 
SARS-3CL(pro) Mukherjee et al. 2008 
E. coli enoyl-ACP-reductase Yao et al. 2010 
HSP90 Hong et al. 2009 
Cdc25B phosphatase Park et al. 2009 
Beta-secretase Xu et al. 2009 
Extracellular signal-regulated kinase 2 Park et al. 2008 
CK1 delta Cozza et al. 2008 
Phosphatase of regenerating liver-3 Park et al. 2008 
S. pneumoniae VicR/K Li et al. 2009 
PPARG Salam et al. 2008 
V. harveyi LuxP Li et al. 2008 
VHR Phosphatase Park et al. 2008 
ErmC Methyltransferase Feder et al. 2008 
Protein tyrosine phosphatase 1B Park et al. 2009 
Insulin-regulated aminopeptidase Albiston et al. 2008 
Human PEBP4 Qiu et al. 2010 
H. pylori UPPS Kuo et al. 2008 
Mammalian proteasome 20S Basse et al. 2010 
Aurora kinase A Coumar et al. 2009 
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Aldo-keto reductase 1C1 Brozic et al. 2009 
Chemokine receptor CCR4 Bayry et al. 2008 
 
The aim of docking is to predict the structure of the complex 
[P+L] = [PL] under equilibrium conditions in water and to 
estimate the Gibbs energy of binding ΔG. ΔG can be described 
by the equation ΔG=ΔH-TΔS (Whitesides and Krishnamurthy 
2005).  Enthalphic factors (ΔH) include steric and electrostatic 
complementary, hydrogen-bonding, protein strain and also 
ligand strain, if the ligand is flexible. Desolvation, rotational and 
translational entropy are important factors in entropy (ΔS). 
 
 
Figure 2.17: The concept of molecular docking. Ligand (L) is docked to the protein (P) 
to form a protein-ligand complex (PL). PDB-Complex 2HU4 (Russell et al. 2006) 
formed by oseltamivir and N1 neuraminidase is closely reproduced by a docking 
program. The docking programs best scored solution is shown in black and that 
experimentally observed in gray. Images created with GLIDE and Maestro 
(Schrödinger Inc). 
 
There are two major components in a docking program: a search 
algorithm that produces relevant binding modes (poses), and a 
scoring function, which should be able to predict the affinity of 
the docked compound to the protein i.e. estimate ΔG. The 
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searching problem has been basically solved, but the scoring 
problem persists. 
Due to the number of atoms involved in the protein-ligand 
interaction, the problem is extremely complex. A typical 
approximation in order to speed up the calculations is to use a 
rigid protein and torsionally flexible ligand instead of a fully 
flexible protein and ligand. Even with these simplifications, 
molecular docking is still a time consuming process compared 
to the ligand-based virtual screening methods. 
There are over 60 docking programs and more than 30 scoring 
functions described in the literature (Moitessier et al. 2008; Viji 
et al. 2009). However, only a fraction of the proposed methods 
are readily available for virtual screening studies. The currently 
available software is listed on Table 2.7 (the references on the 
table are to the latest versions of the programs). Most of the 
docking software is commercial, so licensing might represent a 
rate-limiting step in a virtual screening study even though 
supercomputing capability is available. Commonly used 
docking methods include AutoDock, DOCK, LigandFit, FlexX, 
FRED, GLIDE and GOLD. 
40 
 
  
 
Table 2.7: Currently available docking programs (adapted and modified from 
Moitessier et al. 2008). The most commonly used programs are shown in italics 
(McInnes 2007). License abbreviations: O=Open Source, F=Free, FA=Free for 
Academic use and C=Commercial. 
Program Reference Search 
algorithm 
Lic. Website 
AutoDock Morris et al. 2009 LGA O 
autodock.scripps.
edu 
AutoDock 
Vina 
Trott and Olson 
2010 
Gradient 
optimization 
based 
FA vina.scripps.edu 
CDOCKER of 
Discovery-
Studio 
Wu et al. 2003 
 
MD/simulated-
annealing 
C 
www.accelrys.co
m 
CHARMM 
(Galgor) 
Vieth et al. 1998 GA/MC C www.charmm.org 
DOCK Lang et al. 2009 Sphere matching FA 
dock.compbio.ucs
f.edu 
DockIt - Sphere matching C 
www.metaphorics
.com 
eHiTs 
Zsoldos et al. 
2006 
Rigid docking of 
fragments 
C 
www.simbiosys.c
om 
DAIM-SEED-
FFLD 
Kolb and Caflisch 
2006; Majeux et 
al. 2001; Budin 
et al. 2001 
Docking of 
fragments 
F 
www.biochem-
caflisch.uzh.ch 
FITTED 
Corbeil et al. 
2007 
GA FA www.fitted.ca 
LibDock of 
Discovery-
Studio 
Diller et al. 2001 
 
Pregenerated 
ligand 
conformations 
with gradient-
based 
optimization 
C 
 
www.accelrys.co
m 
LigandFit of 
Discovery-
Studio 
Venkatachalam 
et al. 2003 
 
Shape-based 
method with MC 
C 
 
www.accelrys.co
m 
FlexX 
Rarey et al. 1996 
 
Incremental 
construction 
C 
 
www.biosolveit.de 
FlipDock 
Zhao and Sanner 
2007 
 
GA 
FA 
 
flipdock.scripps.e
du 
FRED 
McGann et al. 
2003 
 
Gaussian docking 
function 
FA 
 
www.eyesopen.co
m 
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FTDock 
Gabb et al. 1997 
 
Fourier 
correlation 
algorithm 
O 
 
bmm.cancerresea
rchuk.org 
GEMDOCK 
Yang and Chen 
2004 
 
GA 
F 
 
gemdock.life.nctu
.edu.tw 
GlamDock 
Tietze and 
Apostolakis 2007 
 
MC 
FA 
 
www.chil2.de 
GLIDE 
Friesner et al. 
2004 
 
MC 
C 
 
www.schrodinger.
com 
GOLD 
Verdonk et al. 
2003 
 
GA 
C 
 
www.ccdc.cam.ac
.uk 
HADDOCK 
de Vries et al. 
2007 
 
Mainly for 
protein-protein 
docking 
FA 
 
www.nmr.chem.u
u.nl 
MolDock 
Thomsen and 
Christensen 2006 
 
Heuristic search 
C 
 
www.molegro.co
m 
PatchDOCK 
Schneidman-
Duhovny et al. 
2005 
Shape 
complementary 
FA 
 
bioinfo3d.cs.tau.a
c.il 
PLANTS Korb et al. 2009 
Ant colony 
optimisation 
FA 
 
www.tcd.uni-
konstanz.de 
ICM 
Abagyan et al. 
1994 
 
MC 
C 
 
www.molsoft.com 
rDock 
Morley and 
Afshar 2004 
 
MC 
F 
 
www.ysbl.york.ac
.uk/rDock 
ROSETTA-
LIGAND 
Meiler and Baker 
2006 
 
MC 
FA 
 
www.rosettacom
monds.org 
SLIDE 
Schnecke and 
Kuhn 2000 
 
Incremental 
construction 
FA 
 
www.bch.msu.ed
u/~kuhn 
SODOCK 
Chen et al 2007 
 
Particle swarm 
optimization for 
AutoDock 3.05 
F 
 
iclab.life.nctu.edu
.tw/sodock 
Surflex-Dock 
Jain 2007 
 
Incremental 
construction 
FA 
 
www.biopharmics
.com 
MOE-Dock - MC C 
www.chemcomp.c
om 
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In the following section, the different types of searching 
algorithms and scoring functions are described briefly. 
Computationally intensive simulation-based methods such as 
free energy perturbation or Molecular Mechanics/Poisson-
Boltzmann-Surface-Area (MM/PBSA) are not discussed here, as 
they cannot be used in high-throughput virtual screening (at 
least not yet). 
2.3.1 Searching algorithms 
Different approaches for the docking pose generation have been 
applied. The methods can be roughly divided into three main 
types: rigid-body, incremental construction and stochastic 
algorithms. 
 
Rigid-body docking 
 
Rigid-body docking algorithms use either single or multi-
conformation databases to account for ligand flexibility 
(Moitessier et al. 2008). The molecules are fitted into the binding 
sites of proteins by shape complementary or by interaction 
matching algorithms. These are the fastest structure-based 
virtual screening methods, but their accuracy may be limited 
due to the fact that ligand conformation is not refined at the 
binding site. They are also highly dependent on the method 
used to create the conformations (see Chapter 2.5). It has been 
suggested that these kinds of methods should be used only for 
initial screening of large libraries. 
An example of rigid-body docking software is FRED from 
OpenEye Scientific Software (McGann et al. 2003). It uses pre-
generated multi-conformation database as its input. First, all 
possible poses of the ligand around the active site are 
enumerated for each of the conformations. These poses are then 
filtered, based on the volume of the active site. The remaining 
poses are then scored with a scoring function. FRED is one the 
fastest docking program currently available, as it requires just a 
few seconds per ligand. Its performance was also comparable to 
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the more computationally intensive GLIDE in an 11 target study 
(McGaughey et al. 2007). 
 
Incremental construction docking 
 
There are also docking programs based on incremental 
construction algorithms. These programs build up the ligand in 
the active site. First, the ligand is fragmented and one fragment 
is selected as the anchor fragment. The anchor fragment is then 
rigidly docked into the active site and the other fragments are 
connected with the knowledge of preferred conformations. 
FlexX is an example of a program that is based on incremental 
construction (Rarey et al. 1996). It uses a pose-clustering 
technique similar to those used in pattern recognition.  
 
Stochastic docking  
 
Both multi-conformation and incremental construction docking 
algorithms are deterministic. There are also stochastic docking 
algorithms available that have a random element in them. 
Therefore, they do not usually produce exactly the same results 
in every run. The two most widely used stochastic approaches 
are Monte Carlo methods and genetic algorithms. 
Monte Carlo methods are based on repeated random sampling. 
The ligand to be docked is randomly rotated and translated one 
parameter at the time. The modified conformation is then 
evaluated by a scoring function. If the new conformation has a 
lower energy than the previous one, it is kept. The process is 
repeated until a satisfactory pose has been generated. A typical 
example of Monte Carlo docking method is ICM (Abagyan et al. 
1994). GLIDE has also a Monte Carlo element, as final poses 
from hierarchical filtering are generated by the Monte Carlo 
method (Friesner et al. 2004). 
Genetic algorithms are based on Darwin’s theory of evolution 
(Moitessier et al. 2008). A docking pose is stored in a data 
structure called a “chromosome”, which is made up of numbers 
called “genes” that store each translational angle, rotation and 
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translation of the ligand. Chromosomes then evolve through a 
process of reproduction and are altered by genetic operators like 
mutation and crossover. The next generation is then selected by 
the survival of the fittest, where the two lowest energy 
chromosomes are kept. Lamarckian Genetic Algorithm (LGA) is 
a modification of the genetic algorithm that is used in AutoDock 
(Morris et al. 2009). LGA is hybrid method which contains an 
adaptive global optimizer with a local search. The local search 
method uses a random search optimization, which is allowed to 
change the chromosome of the global optimizer. The use of LGA 
instead of the regular genetic algorithm increases the 
performance of AutoDock (Morris et al. 1998). 
2.3.2 Scoring functions 
The scoring functions can be roughly divided into force field-, 
empirical and knowledge-based (Kitchen et al. 2004; Moitessier 
et al. 2008). Scoring functions can be also hybrids of molecular 
mechanics and empirical terms (Table 2.8). 
45 
 
  
 
Table 2.8: Currently available scoring functions (adapted and modified from 
Moitessier et al. 2008). 
Scoring 
function 
Reference Type Software or 
website 
ChemScore 
Eldrige et 
al. 1997 
Empirical 
GOLD, FRED, CScore 
 
ShapeGauss 
McGann et 
al. 2003 
Empirical 
FRED 
 
ChemGauss3 - Empirical 
FRED 
 
eHiTs 
Zsoldos et 
al. 2006 
Empirical 
eHiTs 
 
GlideScore 
Friesner et 
al. 2004 
Empirical 
Glide 
 
FlexX 
Rarey et al. 
1996 
Empirical 
FlexX 
 
Hammerhead 
Pham and 
Jain 2006 
Empirical 
Surflex-Dock, 
DiscoveryStudio 
 
LigScore 
Krammer et 
al. 2005 
Empirical 
DiscoveryStudio 
 
PLP 
Verkivker et 
al. 2000 
Empirical 
DiscoveryStudio, FRED, 
DockIt 
 
RankScore 
Moitessier 
et al. 2006 
Empirical/FF 
FITTED 
 
ScreenScore 
Stahl and 
Rarey 2001 
Empirical/consensus 
FRED 
 
SLIDE SCORE 
Schnecke 
and Kuhn 
2000 
Empirical 
SLIDE 
 
X-Score 
Wang et al. 
2003 
Empirical/consensus 
sw16.im.med.umich.edu/soft
ware/xtool 
 
AutoDock4 SF 
Huey et al. 
2007 
FF/Empirical 
AutoDock, SODOCK 
 
DockScore 
Meng et al. 
1992 
FF 
DOCK, Cscore 
 
Zou GB/SA 
Score 
Liu et al. 
2004 
GB/SA 
DOCK 
 
GoldScore 
Jones et al. 
1997 
FF 
GOLD, Cscore 
 
HADDOCK 
van Dijk et 
al. 2006 
FF 
HADDOCK 
 
ICM 
Abagyan et 
al. 1994 
FF 
ICM 
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DrugScoreCSD 
Velec et al. 
2005 
Knowledge based 
pc1664.pharmazie.uni-
marburg.de/drugscore 
 
DrugScorePDB 
Gohlke et 
al. 2000 
Knowledge based 
pc1664.pharmazie.uni-
marburg.de/drugscore 
 
M-Score 
Yang et al. 
2006 
Knowledge based 
sw16.im.med.umich.edu/lab/
members/chaoyie 
 
PMF 
Muegge 
2006 
Knowledge based 
DiscoveryStudio, DockIt, 
Cscore 
 
Zapbind 
Grant et al. 
2001 
Empirical/PBSA 
FRED, DOCK 
 
Astex Scoring 
Potential 
Mooij and 
Verdonk 
2005 
Knowledge based 
GOLD 
 
Cscore 
Clark et al. 
2002 
Consensus 
SYBYL 
 
LUDI 
Böhm et al. 
1998 
 
Empirical 
DiscoveryStudio 
 
ASE - Gaussian 
MOE 
 
London dG - Empirical/FF MOE 
 
Force field-based scoring functions 
 
Molecular mechanics force fields are used in scoring functions to 
calculate the protein-ligand interaction energy and the internal 
ligand energy. The two factors contributing to the energy are 
van der Waals and electrostatic terms. van der Waals energy is 
most often described by a Lennard-Jones potential (also known 
as the 12-6 potential): 
 
ܧ௩ௗ௪ሺݎሻ ൌ෍෍Ͷߝ ൥ቆ
ߪ௜௝
ݎ௜௝
ቇ
ଵଶ
െ ቆ
ߪ௜௝
ݎ௜௝
ቇ
଺
൩
ேಳ
௜ୀଵ
ேಲ
௝ୀଵ
 
 
where NA and NB are the number of atoms in molecules A and B, 
r is the distance between atoms i and j, σ is the collision 
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diameter between atoms i and j, and ε is the well depth of the 
potential.  
Different modifications of Lennard-Jones potential have been 
formulated. For example, the 12-10 potential is used in 
AutoDock to model hydrogen bonding (Morris et al. 2009). 
The electrostatic potential energy is calculated from a 
Coulombic equation: 

ܧ௖௢௨ሺݎሻ ൌ෍෍
ݍ௜ݍ௝
Ͷߨߝ଴ݎ௜௝
ேಳ
௝ୀଵ
ேಲ
௜ୀଵ
 
 
where Nx are the number of atoms in molecule x, ε0 the electric 
constant and qy is the charge of each atom y. 
These kinds of descriptions suffer from obvious serious 
limitations such as modeling protein-ligand binding in water, as 
they were originally formulated to model gas-phase interactions 
and do not take solvation or entropy into account. Furthermore, 
arbitrary cut-off values are required for modeling of non-
bonded interactions, which complicates the estimation of long-
distance interactions. 
Given these limitations, additional terms besides van der Waals 
and Coulombic energy have been added to the scoring 
functions. The AutoDock scoring function includes a 
desolvation potential Esol based on the general approach by 
Wesson and Eisenberg (Wesson and Eisenberg 1992; Huey et al. 
2007). It has an atomic solvation parameter Si and volume Vi of 
the atoms surrounding given atom i: 
 
௜ܵ ൌ ܣ௜ ൅ ܳ כ ȁݍ௜ȁ 
 
ܧ௦௢௟ ൌ෍൫ ௜ܵ ௝ܸ ൅ ௝ܵ ௜ܸ൯݁
൭
ି௥೔ೕ
మ
ଶఙమ൱
௜ǡ௝
 
 
where σ is a distance weighting factor, Ai and Q are atomic 
solvation parameters calibrated using six atom types.  
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Empirical scoring functions 
 
Scoring functions can also take advantage of existing 
experimental data (Kitchen et al. 2004; Moitessier et al. 2008). 
Empirical scoring functions are derived with regression analysis 
from determined binding energies and/or crystallography data. 
The concept was originally implemented in de novo design 
program LUDI (Böhm 1992) and since then, several empirical 
scoring functions have been proposed (Wang et al. 2002). 
Empirical scoring functions are very simple to calculate, but 
obviously their performance is highly dependent on the data set 
from which they are derived. 
 
Knowledge-based scoring functions 
 
Knowledge-based scoring functions are also very quick to 
calculate (Kitchen et al. 2004). They are designed to reproduce 
experimentally observer structures instead of devising 
predictions of affinity like empirical scoring functions. As the 
name implies, knowledge-based scoring functions use data 
about protein-ligand interactions. Pre-defined atom-pair 
interactions are used to evaluate the docking pose. Similar to 
empirical scoring functions, knowledge-based scoring functions 
are limited by the availability of experimental structures. 
Given the limitations of the current scoring functions (see 
Chapter 2.6), there have been many attempts made to combine 
several scoring functions to improve the accuracy (consensus 
scoring) (Clark et al. 2002). The debate still is on-going if 
consensus scoring is actually useful (Brooijmans and Humblet 
2010), as there are both positive (Charifson et al. 1999; Krovat 
and Langer 2004) and negative findings (Verdonk et al. 2004; 
Stahl and Rarey 2001). 
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2.4 DATABASE PREPARATION 
Whenever one chooses ligand- or structure-based approach for 
virtual screening, a molecular database of available compounds 
has to be prepared. While at first glance this step seems trivial, 
there are potential pitfalls for the unwary modeler. 
One must make sure that the molecular database to be screened 
is up-to-date and at least most of the compounds are readily 
available for purchase. It makes little sense to find an interesting 
molecule that one cannot acquire, as the chemical synthesis is 
usually extremely laborious and rarely justified simply on the 
basis of initial virtual screening results. 
A comprehensive and free source for virtual screening databases 
is ZINC, available at zinc.docking.org (Irwin and Shoichet 2005). 
It contains pre-processed databases from the most prominent 
chemical vendors. The current version 10 of ZINC has over 13 
million compounds that are readily available. 
2.4.1 Prefiltering 
Before embarking on computationally intensive 3D virtual 
screening, prefiltering of the database is useful. Simple 
properties like molecular weight or number of rotatable bonds 
can be used to remove compounds that are not wanted. The 
most famous of these simple filters is “the rule of five” (Lipinski 
et al. 1997), which is used to a evaluate compound’s so-called 
druglikeness. It states that an orally active drug should possess 
no more than one violation of the following criteria: 
- less than six hydrogen bond donors 
- less than 11 hydrogen bond acceptors 
- molecular weight below 500 Da 
- CLogP less than five 
It may not make sense to use “the rule of five” as a filter in the 
early lead discovery, as it has been shown that actual drug 
molecules are different from lead molecules (Teague et al. 1999; 
Ohno et al. 2010) and chemical probes (Oprea et al. 2007). A 
good lead needs to be less complex than the actual drug 
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molecule, so that there is room for optimization. Oprea and co-
workers have defined lead-like properties (Oprea et al. 2001): 
- molecular weight below 450 Da 
- ClogP between -3.5 and 4.5 
- less than five ring structures 
- less than 11 nonterminal single bonds 
- less than six hydrogen bond donors 
- less than nine hydrogen bond acceptors 
One should also remove promiscuous compounds (also known 
as “frequent hitters”), molecules that show up as false positives 
in HTS, independent of the target due to reasons not related to 
the protein-ligand interaction (Baell et al. 2010). Reactive and 
undesirable groups should be also removed in the database 
preparation phase (for example, see Lagorce et al. 2008). 
2.4.2 Tautomerism, protonation states and stereoisomerism 
Tautomerism also has an effect on molecular databases (Pospisil 
et al. 2003; Knox et al. 2005). Tautomerism is isomerism of the 
form: 
 
 
 
where the isomers are readily interconvertible (IUPAC 2010).  
This kind of isomer is called a tautomer. The atoms connecting 
groups X,Y,Z are usually carbon, hydrogen, oxygen or sulphur. 
Group G becomes an electrofuge or nucleofuge during 
isomerization. The most commonly known tautomeric 
phenomenon is the proton migration (prototropy), where the 
hydrogen atom moves between different sites on the same 
molecule. This is not to be confused with ionization or 
protonation where the hydrogen atom leaves or comes from 
another molecule. These different protonation states are 
sometimes called protomers in the virtual screening literature 
(not to be confused with the official definition of a protomer, 
which is a structural unit of an oligomeric protein). Other 
examples of tautomerism are keto-enol and ring-chain 
tautomerism.  
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An equilibrium exists between the different tautomeric forms. In 
the aqueous medium, several factors such as temperature and 
pH affect the tautomeric equilibrium. It is therefore non-trivial 
to predict the relative stabilities of different tautomers. Several 
programs are available for rapid tautomer and protonation state 
enumeration, such as QuacPac (OpenEye Scientific Software) 
and LigPrep (Schrödinger Inc.). QuacPac simply enumerates all 
reasonable tautomeric and protonation states in an aqueous 
solvent. LigPrep’s tautomer tool is also based on pre-defined 
tautomeric groups and their assumed probabilities. EpiK 
(Schrödinger Inc.) and MoKa Suite (Molecular Discovery Ltd) 
can also predict the most likely tautomeric and protonation state 
instead of simply enumerating all forms. EpiK is based on Taft 
and Hammett equation parameterized by values from the 
literature and proprietary data. In a comparative study on 
currently available pKa-prediction programs, it was postulated 
that the training set used in EpiK is too small for diverse set of 
predictions (Manchester et al. 2010). The MoKa Suite is based on 
recursive enumeration of tautomers and an empirical tautomeric 
stability prediction method (Milletti et al. 2009). First, tautomers 
are generated by knowledge and aromaticity rules. Then, the 
stability of different tautomers is predicted by using empirical 
data. The predictions are adjusted with pKa-values predicted by 
MoKa (Milletti et al. 2007). MoKa also generates the relevant 
protonation states over a given pH range. 
In addition to tautomerism and protonation states, there is 
stereochemistry to be considered. Normally the molecules that 
are purchasable from chemical vendors are racemic mixtures. 
Therefore, all stereoisomers need to be considered in docking as 
all forms will be present also in the bioassay (Brooks et al. 2008). 
2.4.3 Conformational analysis 
As previously stated, most small molecules are flexible and have 
several three-dimensional conformations. Conformation 
generators perform conformational analysis efficiently for 
virtual screening purposes. Efficiency in this context means that 
they produce a small total number of biologically relevant 
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conformations per molecule in a reasonable time for a large 
number of compounds (Sadowski and Gasteiger 1993; Watts et 
al. 2010). There are two possible outputs from a generator. 
Either it produces a single, low-energy conformation or an 
ensemble of diverse conformations. The selection of the virtual 
screening method then determines which kind of database one 
should use in the screening process. 
Several alternatives for rapid conformation analysis are publicly 
available (Table 2.9). Conformation generators are generally 
based on either numerical methods such as distance geometry 
or more commonly, empirical data (Sadowski and Gasteiger 
1993).
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Table 2.9: Publicly available conformation generators that are suitable for virtual 
screening studies. S=Single, E=Ensemble, L=License, F=Free, FA=Free for Academic 
use and C=Commercial. 
Program Ref. Algorithm S E L Website 
Catalyst 
(Discovery
Studio) 
 
 
- 
 
Systematic 
Search/MM/Random 
Search 
y y C 
www.accelrys.com 
 
OMEGA 
 
Hawkins 
et al. 
2010 
 
Fragment-
based/Torsion 
library/MM 
y y 
F
A 
www.eyesopen.com 
 
MOE/Conf 
 
- 
 
MM/Fragment-
based/Systematic 
Search 
y y C 
www.chemcomp.co
m 
 
Balloon 
 
Vainio 
and 
Johnson 
2007 
 
Distance 
Geometry/GA/MM 
y y F 
users.abo.fi/mivainio
/balloon 
 
CORINA 
 
Gasteiger 
et al. 
1990 
 
Fragment-based y n C 
www.molecular-
networks.com 
 
ROTATE 
 
Schwab 
2003; 
Renner et 
al. 2003 
 
Torsion library/MM y y C 
www.molecular-
networks.com 
 
ConfGen 
Watts et 
al. 2010 
 
MM/Empirical 
heuristics 
y y C 
www.schrodinger.co
m 
 
CONCORD 
 
- 
 
Empirical/MM y n C 
www.tripos.com 
 
CONFORT 
 
- 
 
MM n y C 
www.tripos.com 
 
DG-AMMOS 
 
Lagorce 
et al. 
2010 
 
Distance Geometry/MM y n F 
www.mti.univ-paris-
diderot.fr/fr/downloa
ds.html 
 
Multiconf-
DOCK 
Sauton et 
al. 2008 
Incremental 
construction, 
Systematic Search 
n y F 
www.mti.univ-paris-
diderot.fr/fr/downloa
ds.html 
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Balloon is an example of a modern conformation generator 
based on numerical methods (Vainio and Johnson 2007). It 
creates the initial conformation using distance geometry and 
additional conformations are generated with a genetic algorithm 
designed to preserve the diversity of conformations. In the 
postprocessing step, the conformations are relaxed using a 
MMFF94-like force field. Since Balloon does not utilize of any 
empirical data, it is rather slow compared to other conformation 
generators. 
OMEGA from OpenEye Scientific Software is a hybrid method 
combining empirical information about fragment conformations 
and calculations of molecular mechanics (Hawkins et al. 2010). 
First, the initial conformation is constructed with a fragment 
library. Then, all rotatable torsions are sampled using a 
knowledge-based list of reasonable angles. Finally, the set of 
conformations is sampled with geometric and molecular 
mechanics criteria. It is extremely fast, on average generating a 
conformation for a molecule in 0.2 seconds (Lagorce et al. 2009). 
ConfGen (Schrödinger Inc) is derived from the conformational 
analysis part of the docking program Glide (Watts et al. 2010). It 
uses a combination of molecular mechanics calculations and a 
set of empirical heuristic rules to generate diverse 
conformations. ConfGen has four different levels for 
conformational analysis: very fast, fast, intermediate and 
comprehensive. By default, the fast mode is used, which is 
designed for virtual screening purposes. The fast mode 
produced 13 conformations per molecule in approximately one 
second on average with a modern Intel Core2 2.4GHz system.  
Some comparison studies on conformation generators have been 
published (for example, see Kirchmair et al. 2006 and Chen et al. 
2008). However it is difficult to state with certainty which 
method is the best. There also seem to be some data issues in 
most studies published so far (Hawkins et al. 2010). Even 
though such studies are easy to conduct after a suitable 
benchmark set has been created, most conformation generators 
are commercial and licensing issues complicate those kinds of 
studies. 
55 
 
  
 
2.5 THE LIMITATIONS OF VIRTUAL SCREENING 
Even though virtual screening has been successful in drug 
discovery projects, there are some fundamental limitations in 
both LBVS and SBVS that are good to keep in mind when 
designing new experiments. The issues relating to the validation 
and benchmarking will be discussed in the next chapter, as they 
do not directly link to the virtual screening methods themselves. 
2.5.1 Limitations of LBVS 
The first limitation of LBVS is the classical chicken and an egg 
problem: at least one biologically relevant molecule must be 
identified before database can be screened. This is a major 
limitation as there are many potential targets for which there are 
known ligands available. 
It is unreasonable to expect something completely different from 
a methodology that is based on searching for similar molecules. 
The issue is illustrated on Figure 2.18, which shows two 
inhibitors for the catecholamine-O-methyltransferase (COMT) 
enzyme. They have both low 2D- and 3D-similarities even 
though they have similar biological activities. Total similarity 
based on a single molecule is therefore a relatively limited 
technique. This problem is alleviated by the fact that often 
several active molecules are known. 
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Figure 2.18: Global similarity metrics miss sub-structural similarity. The two ligands 
of the COMT-enzyme have both low 2D- and 3D-similarities. 
 
There is also a clear paradox in the whole fundamental idea of 
finding novel bioactive molecules from LBVS, since there is the 
similarity principle that states that structurally related 
compounds display similar biological activities (Eckert and 
Bajorath 2007). This of course means that the more different 
compounds that there are, the less likely they are going to have 
similar activity (Bohm et al. 2004). Even though there are 
various ways to measure the similarity between two molecules, 
there is always a tradeoff between scaffold hopping and the 
probability of finding an active compound (Figure 2.19). It 
depends on the project if one wishes to find rather similar 
compounds with a high probability of being active or simply a 
large number of diverse compounds (Triballeau et al. 2006). 
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Figure 2.19: The tradeoff between chemical similarity and the probability of finding an 
active compound. 
 
LBVS methods that require molecular alignment of multiple 
compounds, such as pharmacophores, assume that all of the 
active molecules bind in a similar conformation. Aligning 
several active conformations simultaneously is far from trivial, 
as the crystallized structures of protein-ligand complexes have 
well demonstrated. Two commonly used inhibitors of 
phosphodiesterase 5(PDE5), sildenafil and tadalafil, both have 
the same binding pocket, but the alignment is not obvious from 
the molecular structures alone (Figure 2.20). 
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Figure 2.20: The binding conformations of two inhibitors of PDE5-enzyme. Sildenafil 
is in gray (PDB 2H42) and Tadalafil in black (PDB 1XOZ) (Wang et al. 2006; Card 
et al. 2004). 
2.5.2 Limitations of SBVS 
X-ray crystallography is a rather difficult and laborsome science 
and therefore, it is not surprising that the crystal structures of 
most drug targets are not available. The structures of only a few 
G-protein Coupled Receptors (GPCRs) have been successfully 
solved, even though this class accounts for approximately 30% 
of targets of all marketed drugs (Sela et al. 2010). Homology 
modeling-based structures have been used instead, but it is still 
unclear if such models are truly suitable for virtual screening. In 
a recent GPCR modeling and docking contest, most of the 29 
homology models submitted were not accurate enough to 
permit virtual screening (Michino et al. 2009). 
A protein model based on X-ray crystallography is an 
interpretation of experimental data (Davis et al. 2008). Two 
crystallographers may reach different conclusions from the 
same diffraction data. For example, a functional group of the 
bound ligand might be confused with a water molecule. This 
subjective nature of X-ray crystallography is often ignored when 
utilizing structures from Protein Databank. 
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In addition to the issues related to X-ray crystallography, there 
are major problems with current docking methods. The 
assumption that there is a rigid protein over-simplifies the 
modeling of protein-ligand interaction. The inductive effects are 
rarely considered and therefore the binding pocket may be of 
the wrong shape. A greater problem is that a macromolecular 
complex is not a single structure, but an ensemble of structures 
(Bissantz et al. 2010). Changes in conformations of both ligand 
and protein during the binding have a significant impact on the 
binding energy. 
Scoring functions assume that binding free energy can be 
formulated by additive terms from various protein-ligand 
interactions. In reality, different molecular interactions are 
nonadditive and should be designated with different amounts 
of Gibbs energy in different contexts (Dill 1997).  
Another serious deficiency in docking is that it does not take 
enthalpy-entropy compensation properly into account 
(Whitesides and Krishnamurthy 2005). An increase in entropy 
can compensate for a loss in enthalphy (Krishnamurthy et al. 
2006; Ladbury et al. 2010). A good example of this phenomenon 
is the study of Christof and co-workers on a pair of thrombin 
inhibitors (Christof et al. 2007). The cyclopentyl group of the 
first compound was switched to cyclohexyl group in the second 
molecule. Both compounds had identical binding affinity even 
though X-ray crystallography indicated that the cyclopentyl 
group was located inside the binding pocket, whereas the 
cyclohexyl group was not. This similar binding affinity with a 
different binding mode was caused by enthalphy-entropy 
compensation as revealed by isothermal titration calorimentry. 
It is highly doubtful that this phenomenon would have been 
detected from molecular docking studies. 
One can indeed wonder how docking can work at all, given all 
of these problems (Whitesides and Krishnamurthy 2005; Kolb 
and Irwin 2009). There are successful structure-based virtual 
screening studies where novel biologically active compounds 
have been identified, but rarely has the docking pose been 
experimentally validated by comparing it to the crystallized 
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structure (Kolb and Irwin 2009; Bissantz et al. 2010). It is 
therefore possible that at least some of the reported findings are 
either based on crude features like molecular shape or just sheer 
luck. Indeed, for more sophisticated tasks like lead optimization, 
molecular docking does not seem to be a reliable enough 
technique (Warren et al. 2006; Tirado-Rivers and Jorgensen 2006; 
Leach et al. 2006; Enyedy and Egan 2008). 
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3 Validation and 
evaluation of VS methods 
"From combinatorial chemistry to genomics, new concepts or 
technologies that claim to help accelerate drug development have 
arguably been too rapidly embraced without true validation." 
(Quote from the Editorial of Nature Reviews Drug Discovery 6, 
3, 2007) 
 
There have been proposals about hundreds of different virtual 
screening methods. It is rather difficult to say which methods 
are truly useful in finding novel bioactive compounds. There are 
two approaches for validation. In retrospective validation, data 
from the literature is used to evaluate the performance of a 
method, whereas in a prospective validation, the method is 
validated by the discovery of novel bioactive compounds.  
In most cases, the methods have been validated by retrospective 
virtual screening and no prospective results are provided.  The 
risk of retrospective studies is that the method may work 
artificially well with certain data sets and that the results gained 
are not generally applicable. However, prospective studies are 
not conclusive either as active molecules can be found simply by 
luck. After all, history is filled with examples of serendipitous 
drug discovery (Ban 2006). 
When evaluating a virtual screening method, there are two 
points to consider (Sheridan and Kearsley 2002). First, how good 
the methods are at selecting active molecules from a database 
i.e. what is the quantity of hits? Secondly, how novel are the 
chemical structures of the molecules that are predicted to be 
active i.e. what is the quality of hits? This is not trivial matter 
because there is no standardized test set or even a metric 
available to measure the performance of a new method (Geppert 
et al. 2010; Triballeau et al. 2005; Edgar et al. 2000) and the 
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validation of new methods is often rather limited (Good et al. 
2004b; Kolb and Irwin 2009). To paraphrase Lord Kelvin (1824-
1907): one cannot improve current virtual screening methods if 
one cannot measure the performance. 
The output of a virtual screening method is a hit list, which 
contains the database molecules ordered according to their 
likeness to be active. Ideally, active and inactive molecules are 
separated by the score produced in the virtual screening method 
with some threshold T (Figure 3.1). A true positive is a molecule 
that was correctly predicted as being active, while a false 
positive is an inactive molecule that was predicted to be active. 
A true negative is a compound that was predicted correctly to 
be inactive and a false negative is an active compound that was 
predicted to inactive. Generally speaking, virtual screening 
methods tend to produce a high number of false positives. 
 
 
Figure 3.1: Idealized example of a virtual screening hit list (adapted from Triballeau et 
al. 2006) 
3.1 PUBLICLY AVAILABLE DATA SETS FOR VS EVALUATION 
Usually virtual screening methods are validated by 
retrospective screening of a data set, where a number of known 
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actives (ligands) are mixed with supposedly inactive 
compounds (decoys). This is very problematic, since the results 
depend strongly on the data set composition (van Drie 2004; 
Eckert and Bajorath 2007). Some targets are easier than others. 
Decoy molecules can be trivially different from ligands. For 
example, if decoy molecules are much larger than ligands, it is 
trivial to separate the two groups based on a simple descriptor 
like molecular weight. An imbalanced data set can be compared 
to a police identity parade with one black male suspect in a row 
otherwise filled with white females (Nicholls 2008). In addition, 
the different data set composition makes the reliable comparison 
of methods between different studies impossible. 
In order to tackle these problems, Huang and co-workers 
created a publicly available data set called the “Database of 
Useful Decoys” (DUD) (Huang et al. 2006). It contains a large 
and diverse test set of forty targets belonging to various protein 
families such as nuclear hormone receptors, kinases, serine 
proteases, metalloenzymes, folate enzymes, etc. Each target has 
a set of ligand and decoy molecules. 2950 ligands in total were 
gathered from the literature. The decoy molecules were selected 
from Lipinski-compliant subset of the ZINC database using 2D-
fingerprints. These molecules are assumed to be inactive due to 
their dissimilarity to the ligand set. From this set, 36 decoy 
molecules per ligand that had similar calculated physical 
properties were selected. Molecular weight, hydrogen bond 
acceptors, hydrogen bond donors, CLogP and the number of 
rotatable bonds were considered. DUD seems to provide a more 
stringent test than the previously commonly used MDL Drug 
Data Report (MDDR) and it has been utilized in numerous 
recent studies (for example: Faver et al. 2010; Cross et al. 2009; 
Venkatraman et al. 2009; Englebienne et al. 2009; Clark et al. 
2009; Cosconati et al. 2009; von Korff et al. 2009; Hartmann et al. 
2009; Pham and Jain 2008). 
Some important aspects of DUD have been raised after the 
publication of the data set. One of the authors of DUD explicitly 
stated afterwards that DUD is only for benchmarking molecular 
docking and nothing else (Irwin 2008). Indeed, as the DUD 
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decoys have been selected to be 2D-dissimilar from active 
compounds, DUD is clearly unsuitable for benchmarking 2D-
methods. It also produces overoptimistic results for 3D-
methods, since there are many targets where all active 
compounds are trivial analogs of a central structure. There is 
also an imbalance in formal charges between active and inactive 
molecules: 42% of active and 15% of inactive molecules is 
charged. This creates anomalies in enrichment studies.  
There is a filtered version of the DUD available called DUD LIB 
VS that is intended for benchmarking ligand-based virtual 
screening methods (Good and Oprea 2008; Jahn et al. 2009). A 
lead-like filter and a clustering algorithm were applied to 
remove trivial analogs and molecules that would not have 
passed a normal database preparation step. The imbalance 
between formal charges is however still present on the data set 
and the ligand chemical diversity of some targets is still rather 
modest. Since the original publication, DUD has been also 
clusterized for scaffold hopping analyses by Andrew Good. The 
scaffolds are detected with reduced graph assemblies using the 
method of Barker and co-workers (Barker et al. 2003). 
As there is clearly room for improvement in DUD, alternative 
benchmarking data sets have also been proposed. The 
Maximum Unbiased Validation (MUV) data set is based on 
PubChem bioactivity data for both ligands and decoys (Rohrer 
and Baumann 2009). In MUV, decoy molecules have been 
selected to resemble ligands on the basis of simple descriptors. 
These descriptors are vectors containing various atom counts 
combined with hydrogen-bond acceptors/donors, logP, the 
number of chiral centers and the number of ring systems. It has 
been proven extremely challenging for current ligand-based 
virtual screening methods (Tiikkainen et al. 2009). 
There is the recently published ChEMBL (available at 
http://www.ebi.ac.uk/chembldb), a database containing 
approximately 500 000 bioactive compounds, which should 
provide a good starting point for the building of future virtual 
screening benchmarking data sets. It contains information about 
bioactive compounds, their targets and screening data extracted 
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from various high-impact journals. All data is manually 
evaluated and is therefore of higher quality than the PubChem 
data used in MUV (Bender 2010). 
3.2 MEASURING THE QUANTITY: EVALUATING THE HIT RATE 
When measuring the quantity of active molecules from a virtual 
screening method, the recommended metric is the area under 
the curve for Receiver Operating Characteristic plot (ROC AUC) 
(Jain and Nicholls 2008).  ROC analysis was developed during 
World War II for radar applications and since then it has been 
applied in many fields of science. It is a visual as well as 
numerical method for evaluation of different virtual screening 
methods (Triballeau et al. 2005; Sonego et al. 2008). 
ROC analysis can be applied to any binary classification 
problem. In virtual screening, the compounds in the hit list must 
be assigned as being either active (1) or inactive (0). Many 
benchmarking sets already have this classification, as they are 
divided into ligands and decoys. A confusion matrix is 
generated for each threshold in the hitlist, from which 
sensitivity Se and specificity Sp are calculated (Figure 3.2). 
Finally, sensitivity is plotted as a function of 1-specificity to 
form the ROC curve. The integral of this curve (area under 
curve, AUC) is a single numerical measure of ranking 
performance (Sonego et al. 2008). Random ranking produces a 
diagonal curve with AUC of 0.5, while a perfect AUC is 1.0. 
There is no absolute AUC threshold for “good performance”, 
but a virtual screening method should at least produce AUC 
higher than the random ranking (0.5). 
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Figure 3.2: Generation of ROC curves for virtual screening (Triballeu et al. 2005). 
 
The application of ROC AUC to the evaluation of virtual 
screening methods has been criticized, because ROC AUC does 
not take the “early enrichment problem” into account (Truchon 
and Bayly 2007; Kirchmair et al. 2008). As only the top of the 
hitlist can be normally tested for biological activity, early 
enrichment is an important issue. The problem is illustrated on 
Figure 3.3, where there are two idealized curves with the same 
ROC AUC. Both curves have the same AUC of 0.5 even though 
the hitlists are clearly different. The dashed line is simply 
random and the solid line is from a hitlist where 50% of actives 
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are retrieved at the top and 50% at the bottom. It is however 
debatable if such extreme biphasic behavior could really be 
observed in real life virtual screening scenarios (Nicholls 2008). 
 
 
Figure 3.3: "The early enrichment" problem. Both solid and dashed curves have the 
same ROC AUC. 
 
The most common metric to measure the early enrichment is the 
Enrichment Factor (EF) (Jacobsson et al. 2003; Hecker et al. 2002; 
Diller et al. 2003; Triballeau et al. 2006): 
 
ܧܨ ൌ
௣ܶ
௦ܰ௨௕௦௘௧
ܮௗ௔௧௔௕௔௦௘
ௗܰ௔௧௔௕௔௦௘
 
 
where Tp is the number of true positives, Nsubset the number of 
molecules in a given cutoff, Ldatabase the total number of actives in 
the data set and Ndatabase the total number of molecules in the data 
set. 
There are two problems associated with EF i.e. it relies on an 
arbitrary cutoff (the subset size) and it is dependent on the ratio 
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of the active molecules in the database, which makes 
comparisons between different studies impossible (Kirchmair et 
al. 2008; Nicholls 2008). The cutoff issue can be examined by 
calculating several EFs at different cutoffs, but this complicates 
the interpretation of the results. 
To reduce the effect of the arbitrary cut-off value, Robust Initial 
Enrichment (RIE) was developed by Sheridan and co-workers 
(2001): 
 
ܵ ൌ ෍ ݁ି
ோ೔
ேೌ೎೟೔ೡ೐ೞ
ேೌ೎೟೔ೡ೐ೞ
௜
 

ܴܫܧ ൌ
ܵ
ۃܵۄ
 
 
where Nactives is the number of active molecules in the hit list, Ri is 
the rank of the active compound I and <S> is the mean S 
calculated from 1000 trials where the ranks of active compounds 
are randomized. 
RIE has its own limitations, e.g. it is difficult to reliably compare 
two RIE values, and therefore a new metric called the 
Boltzmann-enhanced discrimination of the receiver operating 
characteristic (BEDROC) was developed (Truchon and Bayly 
2007). It is a weighted ROC AUC which means that the top of 
the hit list is weighted more than the rest. The mathematics 
behind BEDROC are complicated, but the authors provide C++ 
and Python codes for calculating BEDROC values from simple 
hit lists. However, it is not clear if the RIE or BEDROC provides 
any extra value over ROC AUC when evaluating virtual 
screening methods (Nicholls 2008; Geppert et al. 2010). 
The metrics used for measuring the retrieval effectiveness of 
information retrieval systems can be readily applied in virtual 
screening validation (Table 3.1) (Edgar et al. 2000; Triballeau et 
al. 2006). Similar to EF, these metrics suffer from the problem of 
an arbitrary cut-off for subset selection. 
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Table 3.1: Different metrics for the assessment of virtual screening performance (Edgar 
et al. 2000; Triballaeu et al. 2006; Bradley et al. 2000, 2003; Matthews 1975; Diller et 
al. 2001; Guha and Jurs 2005; Weston et al. 2003; Güner and Henry 2000).  The 
variables in the formulas:  the number of selected molecules Nsubset, the number of 
screened molecules Ndatabase, the number of active molecules in the database Ldatabase and 
the number of active molecules in the hit list Lsubset. 
Metric Formula 
Recall/sensitivity (R, Se) 
 
ܮ௦௨௕௦௘௧
ܮௗ௔௧௔௕௔௦௘
 
Precision/hitrate (P) 
 
ܮ௦௨௕௦௘௧
௦ܰ௨௕௦௘௧
 
Fallout (F) 
 
௦ܰ௨௕௦௘௧ െ ܮ௦௨௕௦௘௧
ௗܰ௔௧௔௕௔௦௘ െ ܮௗ௔௧௔௕௔௦௘
 
Generality (G) 
 
ܮௗ௔௧௔௕௔௦௘
ௗܰ௔௧௔௕௔௦௘
 
Vickery 
 
ͳ
ቀʹܲቁ ൅ ቀ
ʹ
ܴ െ ͵ቁ
 
ͳ
ቀͳܲቁ ൅ ቀ
ͳ
ܴ െ ͳቁ
 
van Rijsbergern (α is the 
relative importance of the 
precision) 
 
ͳ
ߙ ቀͳܲቁ ൅ ሺͳ െ ߙሻቀ
ͳ
ܴቁ
 
Cosine coefficient 
 
ξܴܲ 
Discrimination ratio 
 
ܵ݁
ܵ݌
 
Information content 
 
௣ܶ 
௣ܶ
ܨ௣
൅ ܨ௡ 
ܨ௡
௡ܶ
 
Matthews correlation 
coefficient 
 
௣ܶ ௡ܶ െ ܨ௡ܨ௣
ටሺ ௡ܶ ൅ ܨ௡ሻ൫ ௡ܶ ൅ ܨ௣൯൫ ௣ܶ ൅ ܨ௡൯൫ ௣ܶ ൅ ܨ௣൯
 
GH score 
 
൬
͵
Ͷ
ܲ ൅
ͳ
Ͷ
ܴ൰ܵ݌ 
Ford’s M (ω is an weighting 
factor), “balanced labeling 
performance” when ω=0.5  
 
߱ܵ݁ ൅ ሺͳ െ ߱ሻܵ݌ 
Statistical significance 
 
෍
ቀܮௗ௔௧௔௕௔௦௘
݇
ቁ൬ ௗܰ௔௧௔௕௔௦௘ െ ܮௗ௔௧௔௕௔௦௘
௦ܰ௨௕௦௘௧ െ ݇
൰
൬ ௗܰ௔௧௔௕௔௦௘
௦ܰ௨௕௦௘௧
൰
௅೏ೌ೟ೌ್ೌೞ೐
௞ୀ ೛்
 
Analysis of efficiency (U is 
the n of mols. with unkown 
activity) 
ͳ
ʹ
ሺܵ݁ ൅ ܵ݌ሻሺͳ െ ௦ܷ௨௕௦௘௧
ௗܷ௔௧௔௕௔௦௘
ሻ 
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3.3 MEASURING THE QUALITY: EVALUATING THE CHEMICAL 
DIVERSITY AND SCAFFOLD HOPPING 
When evaluating if scaffold hopping has occurred or not, a well-
defined criterion for scaffolds should be available (Jenkins et al. 
2004; Brown and Jacoby 2006; Schneider et al. 2006; Mackey and 
Melville 2009). The scaffold criterion should also be independent 
of the algorithm used in the virtual screening. There are two 
aspects to this problem: first, the definition of a scaffold and 
secondly, the quantification of scaffold retrieval (Figure 3.4). 
Most publications seem to define scaffolds based on molecular 
frameworks – the concept introduced by Bemis and Murcko 
(Chapter 2.3). Original Bemis and Murcko molecular 
frameworks are simply graphs without any atom information, 
but often different heterocyclic structures are considered as 
different scaffolds (Lipkus et al. 2008). This makes sense from 
both the synthetic chemistry and chemical information point of 
view. Connecting two piperidine rings is different than 
connecting two cyclohexane rings. Both structures also have 
clearly different electrostatic properties and thus probably 
different biological properties. However, the heterocyclic 
scaffold definition introduces some new issues. For example, 
should piperidine and piperazine be considered as different 
scaffolds? 
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CLUSTERING
1. Definition of scaffolds
2. Quantification of scaffold retrieval
SOME METRIC SCALARVALUE
MOLECULE SCAFFOLDRANK
1
2
3
 
Figure 3.4: The two steps required in objective scaffold hopping quantification. 
 
Most of the current objective scaffold definition methods are 
based on 2D-properties and do not take 3D-similarity into 
account. Scaffolds are still often subjectively defined and not 
numerically measured (Bender et al. 2004; Jenkins et al. 2004; 
Zhang and Muegge 2006; Williams 2006; Good et al. 2004b). 
Some studies have calculated 2D-fingerprints and Tanimoto 
coefficients in order to show scaffold hopping (for example, 
Saeh et al. 2005), but there is the problem of choosing the 
optimal threshold value i.e. when the two scaffolds are different. 
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Clustering of 2D-properties has been used to define scaffolds in 
several recent studies (Stiefl et al. 2006; Vidal et al. 2006; Krier et 
al. 2006). Selector from Tripos (part of the SYBYL molecular 
modeling package) is one of the first classification programs for 
undertaking library diversity analysis (Martin 2001). Selector 
can use several diversity metrics such as UNITY 2D fingerprints, 
3DFlex fingerprints, atom pair distances, CLOGP, QSAR 
derived parameters, substituent constants and CoMFA columns. 
There are also three different classification algorithms 
implemented in Selector (hierarchical clustering, Jarvis-Patrick 
clustering and reciprocal nearest neighbor clustering). Other 
similar tools are available from ChemAxon (Borosy et al. 2001; 
Vargyas et al. 2006) and Simulations Plus (Krier et al. 2006). The 
problem with all automatic clustering programs is that two 
different similarity metrics define different scaffolds and the 
scaffolds may appear arbitrary (Medina-Franco et al. 2009). The 
issue of scaffold definition is clearly a complex subject which 
needs to be clarified. 
There is still the issue of quantification of the scaffold retrieval 
even if one uses pre-defined scaffold definitions. Such metric 
would be a very useful tool in the validation and evaluation of 
virtual screening methodologies (Good et al. 2004b). The 
intuitive “the fraction of retrieved scaffolds in the top of hitlist” 
has been used in most studies assessing scaffold hopping in 
virtual screening, but it also has some issues as recently pointed 
out (Mackey and Melville 2009). For example, the scaffolds that 
are present in a large number of compounds are more likely to 
be found by random than those scaffolds that are only in few 
molecules in the data set. Overall, there is still not any generally 
accepted metric available for the objective evaluation of scaffold 
hopping, but recently some metrics have been proposed that 
may perhaps represent at least a partial solution to the problem 
(Krier et al. 2006; Clark and Webster-Clark 2008; Mackey and 
Melville 2009; Medina-Franco et al. 2009).  
Krier and co-workers proposed a new metric called PC50C 
(Krier et al. 2006). It is computed from the percentage of scaffold 
classes accounting for 50% of the classified compounds. Medina-
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Franco and co-workers further developed this line of thought 
with scaffold retrieval curves and a metric called Scaled 
Shannon Entropy (Medina-Franco et al. 2009). The way that 
these methodologies could be applied to the virtual screening 
would be to analyze the diversity of the active molecules in the 
top of the hitlist selected. However, this strategy has not yet 
been investigated. 
Clark and Webster-Clark suggested the addition of weights to 
ROC curves accounting for the measurement of scaffold 
hopping (Clark and Webster-Clark 2008). Their idea was 
recently refined in a study by researchers at Cresset 
Biomolecular Discovery (Mackey and Melville 2009). In this 
study, scaffold hopping weighted ROC AUC, EF and other 
weightings for enrichment metrics were developed. It was 
shown that the difference between the DUD COX2 active 
molecules (relatively few scaffolds) and FXA active molecules 
(more diverse set) could be detected. These two extreme cases 
were easy to identify, but for other targets the quantification 
was not so clear. More studies will be required to confirm the 
usefulness of this interesting technique. As Mackey and Melville 
provide free software to calculate their metrics, conducting such 
a study might be rather straightforward. 
Given the controversial current status of scaffold hopping 
quantification (Geppert et al. 2010), pre-defined 2D-scaffold 
definitions with a simple metric “the fraction of retrieved 
scaffolds in the top of the hitlist” are used in assessing of early 
scaffold hopping in the experimental part of this thesis: 
 
ܨ௑ ൌ
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where Sfound is the number of the scaffolds found out of all 
possible scaffolds Sall in the top X of the hit list. This metric is a 
”First Found” technique since each scaffold is counted only once 
(Mackey and Melville 2009). 
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4 Aims of the study 
The aim of study was to improve current 3D-virtual screening 
protocols by reducing the number of required calculations, 
while maintaining roughly the same accuracy as measured by 
enrichment and chemical diversity. The more specific aims of 
the study were: 
 
1. to develop a fast molecular field-based method for 
ligand-based virtual screening that could be used when multiple 
similarly binding ligands are known in order to overcome the 
limitations of total similarity (FieldChopper) 
2. to validate and benchmark FieldChopper with a diverse 
data set by retrospective virtual screening and apply the 
technique for ADMET-predictions 
3. to assess the impact of ligand-based tautomer and 
protonation state prediction on molecular docking in order to 
speed up the structure-based virtual screening 
4. to increase the throughput of shape-based virtual 
screening with GPU-computing and reduced conformational 
analysis 
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5 Development and 
validation of 
FieldChopper 
FieldChopper is a novel method for LBVS that can be used 
when multiple, similarly binding active ligands are known. 
Here, the algorithm is described and its performance is 
evaluated. For a more detailed description of the 
implementation, the reader is referred to the licentiate thesis 
(Kalliokoski 2008). The chapter is adapted with permissions 
from: Kalliokoski T, Rönkkö T, Poso A: FieldChopper, A New 
Tool for Automatic Model Generation and Virtual Screening 
Based on Molecular Fields. Journal of Chemical Information and 
Modeling 48: 1131-1137, 2008.  Copyright © 2008 American 
Chemical Society. 
5.1 INTRODUCTION 
Molecular fields describe the properties of a compound by the 
potential around the molecule. They have been applied for 
virtual screening. The seminal work in this area is CoMFA, 
which is the mostly commonly used 3D-QSAR method (see 
Chapter 2.3.3). Putta and co-workers (2002) developed a method 
in which molecules are represented in a binary shape-feature 
descriptor space as bit-strings and the molecule’s relative 
activity is used to identify the subset of the bit-string that is 
most relevant to that activity. This subset is then used as a 
model for virtual screening. The method was evaluated using 
two retrospective virtual screenings of thrombin inhibitors 
(Srinivasan et al. 2002). The model was constructed using 38 
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active molecules and 2418 inactive molecules. In the first virtual 
screening, this model was used to filter the MDDR database. 
MDDR was pre-filtered down to a set of 35462 molecules, which 
contained 540 known thrombin inhibitors. The shape-feature 
based method selected 507 compounds, from which 181 were 
known active molecules. The average enrichment was 2.7 times 
greater compared to 2D-fingerprints. In a second screening, the 
same model was used to screen a small, in-house synthetic 
library of 634 compounds, which contained 64 known active 
molecules. The shape-feature based method selected 109 
compounds, from which 15 were active. The enrichment ratio 
was 1.4 and considering that a random selection should on 
average result in enrichment of 1.0, one can conclude that these 
results are exploratory at the best. 
Jain (2004) has developed Surflex-Sim, a method for ligand-
based structural hypotheses for use in virtual screening. These 
hypotheses are built by aligning a set of active compounds by 
using a molecular fragmentation and incremental construction 
algorithm. The algorithm is rather computationally expensive, 
since it takes several hours on a modern desktop computer. 
Only two to three compounds are used to build a model. Virtual 
screening is done by superimposing the new compound against 
each active compound used in the model. The superimposition 
that has maximum mean similarity against all active compounds 
in the model is returned after being given a score from 0 to 1. 
Surflex-Sim was evaluated using a diverse test set of 22 targets 
(Cleves and Jain 2006). A total of 979 active drug molecules were 
mixed with 850 inactive molecules from Available Chemicals 
Directory. Models were built using one to three active 
compounds. The ability of the models to identify cognate drugs 
against a background of screening molecules showed excellent 
enrichment in 20 out of 22 cases. 
Comparative Molecular Active Site Analysis (CoMASA) uses a 
set of active compounds, which are used to generate a 3D map 
(Kotani and Higashiura 2004). This map can then be used for 
building of queries for virtual screening. CoMASA has not been 
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developed any further, but the method is conceptually similar to 
FieldChopper described in this chapter.  
An overview of FieldChopper is shown in Figure 5.1. First, a 
template molecule for superimposition is selected which is used 
in both model generation and scoring algorithms. A model is 
built by superimposing a set of bioactive molecules onto the 
template molecule and running the model generation algorithm. 
Then, a 3D multi-conformation database is screened by 
superimposing the compounds onto the same template and 
scoring them against the model. Finally, the scores are saved in 
a hit-list that can be used in the selection of compounds for in 
vitro testing. For practical purposes, the superimposing method 
has to be fast enough to handle thousands of molecules within a 
reasonable time. For example, the previously described ROCS 
and BRUTUS are these kinds of methods. 
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Figure 5.1: The overview of the FieldChopper method. 
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5.2 PREPARATION OF THE DATA SET 
The method was developed and validated by a data set 
prepared from the DUD. After the publication of this study, 
several issues have been raised concerning DUD (see Chapter 
3.1). With the benefit of hindsight, it is likely that the results 
obtained here are over-optimistic and lower enrichments would 
be observed in reality. However, the main conclusions of the 
original publication are still valid. 
 
5.2.1 Selection of targets 
Twelve targets from DUD’s 40 targets were selected for this 
study based on the number of ligands (Table 5.1), having at least 
50 active ligands. All other protein classes are included except 
for the metalloenzymes, which were excluded because there 
were not enough ligands in DUD for any of the metalloenzymes. 
 
Table 5.1: Selected Targets for Retrospective Virtual Screening and Number of 
Ligands and Decoys. The ligands used in the models (15 per target) are not included. 
Target Ligands Decoys 
ACHE 90 3714 
AR 59 2628 
COX2 333 12464 
DHFR 186 7145 
EGFR 429 14894 
ERagonist 52 2355 
FGFR1 103 4205 
FXA 127 5095 
GR 63 2797 
INHA 70 3035 
P38 241 8387 
SRC 140 5793 
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5.2.2 Decoy Sets 
As suggested in the original DUD paper, two decoy sets were 
created. The “own decoys” set contains the DUD decoys 
selected for the target, and the “combined decoys” set consists 
of all the decoys used in the selected 12 targets combined 
together. This “combined decoys” consists of about 60% of the 
DUD decoys, so direct comparisons cannot be made with the 
“amalgamated test set” in the original DUD paper. The 
“combined decoys” set is used to simulate a virtual screening 
scenario, where there would be a larger number of 
heterogeneous compounds available. 
5.2.3 Conformation Generation and Calculation of Partial 
Charges 
Since all the methods used in this study consider molecules as 
rigid structures, conformations had to be pregenerated using 
OMEGA (see Chapter 2.5.3) with the MMFF94s force field. The 
number of conformations was limited to ten for the virtual 
screening sets. Partial charges were assigned using the MMFF94 
method implemented in MolCharge from OpenEye Scientific 
Software. 
5.2.4 Molecule Superimpositioning 
To study the effect of different alignment algorithms on 
FieldChopper’s virtual screening accuracy, the alignments were 
produced with BRUTUS and ROCS (see Chapter 2.3.4). The 
three highest scoring molecular alignments for each 
conformation were included into the screening database for 
FieldChopper. As previously discussed, the main difference 
between these two alignment methods is the way that molecular 
energy fields are represented. ROCS employs a set of analytic 
Gaussian functions, while BRUTUS is a grid-based method. 
ComboScore with default ImplicitMillsDean force field was 
used to score the superimposed structures with ROCS and the 
default total score was used in scoring of BRUTUS alignments. 
Template molecules for alignment were taken in their bioactive 
conformation from the Protein Databank using the same crystal 
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structures as in the original DUD paper. Atom and bond types 
of template molecules were corrected with SYBYL version 7.1. 
Hydrogen atoms and partial charges with MMFF94 were added 
using the same software.  
The template molecule selected for alignment might not have 
been ideal in some of the cases studied here. For example, the 
template molecule for FGFR1 seems to be on average smaller 
than a molecule in the ligand set (Table 5.2). Most likely the 
prediction accuracy could have been improved by considering 
other ligands as template molecule for alignment. However, 
then the results would have been difficult to compare due to the 
arbitrary selection of the alignment template molecule. In 
general it seems that the template molecules being used are 
roughly of the same size or slightly larger than the ligand 
molecule on average. 
 
Table 5.2: Molecular weight (MW), surface area (SA) and number of heavy atoms 
(HA) for the alignment templates and ligand sets 
 Template molecule Ligand molecule average 
Target MW SA HA MW SA HA 
ACHE 393 684 28 344 613 25 
AR 284 494 21 327 509 23 
COX2 458 590 26 383 584 26 
DHFR 469 723 33 339 563 24 
EGFR 399 712 29 357 561 24 
ERagonist 333 527 24 286 286 21 
FGFR1 345 586 25 430 682 30 
FXA 470 683 31 452 711 33 
GR 392 546 28 384 585 27 
INHA 407 653 30 373 611 27 
P38 549 875 39 369 606 27 
SRC 506 770 36 411 649 28 
. 
5.2.5 Model building 
The active molecules that are selected have a large impact on the 
model and its performance. A FieldChopper model should have 
a diverse selection of active compounds with different chemical 
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scaffolds. They should also be superimposable into each other. 
Subjective selection of compounds by a human investigator 
would introduce significant bias into the study. To ensure 
objective selection of compounds for the FieldChopper models, 
the following semi-automatic protocol was applied. Since the 
activities for DUD ligands were not readily available, 
compounds were only considered to be either active or inactive. 
To maximize the chemical diversity of the model compounds, 
GRIND-descriptors for the ligands were calculated using three 
probes (DRY, O carbonyl, and N amide). Then, two-component 
principal component analysis was performed with ALMOND. 
From these analyses, 15 compounds were selected for each 
target using the Kennard-Stone uniform subset selection 
algorithm as implemented by Daszykowski and co-workers 
with GNU Octave (Daszykowski et al. 2002). The compounds 
used in the FieldChopper models were removed from all virtual 
screening data sets. 
BRUTUS was used to superimpose the compounds used in the 
model. Three possible solutions were generated for each 
molecule. From these superimpositions, the best one for the 
model was selected by visual inspection. 
5.3 ALGORITHMS 
The most important FieldChopper algorithms are those 
constructed for model generation and scoring. FieldChopper 
uses the electrostatic potentials and van der Waals volumes to 
describe molecules. One common way to represent these fields 
is to use a rectilinear 3D-lattice that is equally spaced and to 
calculate the interaction between the molecule and a probe atom 
in each grid point. This approach was utilized in the previously 
described CoMFA. FieldChopper uses grid-spacing of 1 Å by 
default and a sp3 carbon with a charge of +1.0 as a probe atom. 
The size of the grid is determined according to the molecules 
being examined in the model. 
The van der Waals volume is approximated as 
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where v is the van der Waals radius for the atom; and r is the 
distance between the grid point and the atom. 
The electrostatic potential can be calculated with the following 
equation based on Coulomb’s law (Dill and Bromberg 2002): 
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where k is a conversion factor; Q is the partial charge on the 
atom; and r is the distance between the grid point and the atom. 
5.3.1 Model Generation Algorithm 
In standard pharmacophore methods that result in a model, all 
of the compounds used to form the hypothesis on the possible 
binding mode should have similar, high biological activity 
(Poptodorov et al. 2006), although it has been suggested that it 
might also be useful to use low activity compounds (Dixon et al. 
2006). On the other hand, 3D-QSAR methods (like CoMFA) 
require a diverse activity range for ligands contributing to the 
model (Höltje et al. 2008). FieldChopper considers molecules to 
be either active or inactive. The user must decide what 
an”active” compound is and thus what is an”inactive” 
molecule. For example, some kind of potency, e.g. an IC50 
value, could be used to distinguish between active and inactive 
compounds. 
A reference molecule to act as the template molecule for 
superimposition is needed. This molecule should be in the 
bioactive conformation and be large enough so that the whole 
set of active compounds can be superimposed onto it. The same 
molecule is used to superimpose molecules during the database 
screening phase. 
The model generation algorithm detects similar grid points 
between active compounds. Each grid point is analyzed one at a 
time. The values from active molecules are classified into three 
bins (Table 5.3) for each point. This results in the creation of a 
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three-class histogram from which the peaks are detected. If the 
class frequency is over one-third of the sum of classes, then it is 
classified as a peak. The amount of the peaks can vary from zero 
to two peaks within one histogram. 
 
Table 5.3: Classification limits for the van der Waals and Electrostatic Potentials 
Interaction Bin 1 Bin 2 Bin 3 
van der Waals inside (>=1) 
near 
(>=0.001, 
<=1.0) 
outside 
(<0.001) 
electrostatic negative (<-0.1) 
near zero 
(>=-0.1, 
<0.1) 
positive 
(>=0.1) 
 
The peaks are used in the scoring algorithm. Since most of the 
electrostatic grid is empty, important grid points for the activity 
are detected using the van der Waals histograms. The grid 
points having a peak in their “Near Molecule” bin are taken into 
the electrostatic scoring, and all other points are excluded. For 
the van der Waals volumes, all grid points are used in the 
scoring, since a van der Waals volume describes the overall 
shape of the binding site. Classification limits for the van der 
Waals histograms are selected so that compounds larger than 
those used in the model are punished in the scoring algorithm. 
In order to obtain an overview of the FieldChopper models, an 
analysis of peak distributions was performed. The numbers of 
different peaks are presented in Tables 5.4 and 5.5. The models 
displayed a very similar distribution of the van der Waals peaks. 
The reason for this phenomenon is that the template molecules 
used for alignment are roughly of the same size. The differences 
in “Outside” peaks in the van der Waals scoring are attributable 
to larger grid boxes for certain targets. No histograms with 
“Inside&Outside” or “None” peak cases were found in van der 
Waals material. With respect to the electrostatics, the nuclear 
hormone targets (AR, ERagonist, and GR) had distributions 
different from the other targets. This reflects their partial 
charges which are close to zero in most cases. Positive 
electrostatics seem to be dominant, which is due to the 
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positively charged nitrogen atoms in the original DUD data. 
This revealed the bias in the DUD data set, which was later also 
identified by others (Irwin 2008). 
 
Table 5.4: van der Waals Peak Distributions in Models (1Å Resolution). I=Inside, 
N=Near, O=Outside 
Target Points I I&N N N&O O 
ACHE 24025 272 272 4307 1191 17983 
AR 16675 240 200 3582 850 11803 
COX2 15341 243 238 3631 854 10375 
DHFR 15525 210 270 3586 1286 10173 
EGFR 18975 259 248 4035 1196 13237 
Eragonist 14283 235 191 3468 791 9598 
FGFR1 22599 256 301 4199 1535 16308 
FXA 27869 292 313 4442 1374 21448 
GR 16875 292 247 4029 969 11338 
INHA 19251 287 239 4084 1217 13424 
P38 22707 213 354 3825 1941 16374 
SRC 25839 220 316 3920 1656 19727 
. 
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Table 5.5: Electrostatics Peak Distributions in Models (1Å Resolution). Only those 
peaks are shown that are included in the scoring process (points near the surface). 
Target Points - - / 
0 
- / 
+ 
0 0 / + + N 
ACHE 24025 0 2 31 4 211 4791 1 
AR 16675 180 628 38 2123 857 211 21 
COX2 15341 262 321 287 1025 1313 920 42 
DHFR 15525 59 188 406 276 2175 1111 149 
EGFR 18975 20 28 231 27 2132 2238 9 
Eragonist 14283 95 333 79 2513 729 145 19 
FGFR1 22599 12 29 840 30 1149 3024 18 
FXA 27869 2 2 105 16 501 4604 3 
GR 16875 61 531 90 2833 700 265 20 
INHA 19251 128 135 272 106 3024 1096 8 
P38 22707 1 21 153 17 2633 2156 9 
SRC 25839 2 32 175 55 2349 2229 16 
 
Since there were positively charged compounds in the model, 
active and inactive compounds were mostly differentiated by 
fitting into “positive” peak. This is an anomaly caused by the 
careless preparation of the DUD set which biases all 
comparisons made with electrostatic methods and DUD. 
5.3.2 Scoring Algorithm 
The scoring algorithm requires a previously generated model 
and a superimposed 3D-molecule as input data. The van der 
Waals volume and the electrostatic potential are generated, and 
each grid point is scored. First, the grid point is classified into 
one of three classes described in the model generation 
algorithm. Then, this class is compared with the peaks in the 
model and scored using the scoring matrices (Tables 5.6 and 
5.7). The score for a field is simply the sum of values from the 
scoring matrices. The total score is defined as 
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where S is the total score; WV is the weight for the van der Waals 
score; PV is the van der Waals score; WE is the weight for the 
electrostatic score; and PE is the electrostatic score. 
 
Table 5.6: van der Waals Scoring Matrix. 
Model Molecule 
Peak(s) Inside Near Outside 
Inside 1 -5 -5 
Inside / Near 1 1 -5 
Inside & Outside 1 -5 1 
Near -10 1 -5 
Near / Outside -10 1 1 
Outside -10 -5 1 
None 1 1 1 
 
Table 5.7: Electrostatic Scoring Matrix. 
Model Molecule 
Peak(s) - 0 + 
- 2 0 -2 
- / 0 1 1 0 
- / + 1 0 1 
0 0 1 0 
0 / + 0 1 1 
+ -2 0 2 
None 0 0 0 
 
Since there are fewer points in the electrostatic score than in the 
van der Waals score, the latter score needs to be scaled down. In 
this study, arbitrary values of 0.2 for WV and 1.0 for WE were 
selected. It should be noted that these values are probably not 
optimal, and the weights should be modified according to the 
nature of the target. 
The effect of grid spacing was studied on one target from each 
protein family that had an ROC AUC value approximately 
equal to 0.8 or higher at 1 Å resolution (Table 5.8). It seems that 
the spacing of 1 Å or 2 Å is optimal for most cases. Surprisingly, 
grid spacing of 5 Å still yields high ROC AUC for COX2 and 
FXA. This illustrates the artificial nature of the DUD data set. 
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Also, such crude spacing leads to several ties in the hit-list and 
thus complicates the selection of the top compounds. 
 
Table 5.8: Effect of Grid Spacing on Selected Models: ROC AUCs for “Own Decoys” 
Sets. 
 Grid Spacing 
Target 0.5Å 1.0Å 2.0Å 5.0Å 
AR 0.802 0.803 0.807 0.640 
COX2 0.901 0.896 0.897 0.868 
DHFR 0.830 0.830 0.835 0.733 
EGFR 0.805 0.798 0.814 0.691 
FXA 0.914 0.915 0.915 0.907 
mean 0.851 0.849 0.853 0.768 
median 0.830 0.830 0.835 0.733 
 
The classification limits can also be adjusted. The default 
classification limits were used in retrospective screening, since 
they produced the highest average ROC AUC (Table 5.9). 
However, the differences in accuracy between different 
classification limits are small. It is possible that different limits 
should be used for different kinds of targets, but that would 
require undertaking a completely new study. 
 
Table 5.9: Different Classification Limits: ROC AUCs for “Own Decoys” Set. 
Target 0.5*limits Normal 2*limits 
AR 0.809 0.803 0.762 
COX2 0.879 0.896 0.903 
DHFR 0.797 0.830 0.833 
EGFR 0.738 0.798 0.810 
FXA 0.911 0.915 0.919 
mean 0.827 0.849 0.845 
median 0.809 0.830 0.833 
 
The orientation of molecules in the model is a critical step. This 
is illustrated in Figure 5.2, which shows two different 
FieldChopper models for AR. Both had the same crystal 
structure as a starting point. In one of the models, the 
coordinates of crystal structure were transferred to another 
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position. The two models have different performances, which is 
probably due to the differences in molecular alignments. This is 
a major problem with FieldChopper. However, a similar 
problem exists with other grid-based methods like CoMFA 
(Doweyko 2004). 
 
 
Figure 5.2: The effect of orientation of the molecules in the model. ROC curves for two 
different FieldChopper models (AR, own decoys set). The original model (solid line) 
outperforms the new model (dotted line). 
5.4 RETROSPECTIVE VIRTUAL SCREENING 
Since FieldChopper requires information on several active 
compounds instead of a single ligand, it should outperform 
similarity metrics which rely only on a single active 
conformation. EON (see Chapter 2.3.4) was selected for an 
example of this kind of ligand based-virtual screening method. 
EON has been successfully used in virtual screening to identify 
novel bioactive ligands (Muchmore et al. 2006; Naylor et al. 
2009) and its throughput is similar to FieldChopper. 
In this study, compounds were ranked with EON using the 
default ET_Combo score. The molecules used for alignment 
from Protein Databank were also used in the EON similarity 
calculations. 
The highest ranked alignment was used as a score for the 
compounds. ROC curves and ROC AUCs were calculated with 
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the ROCR package. The Wilcoxon signed ranks test was used to 
assess the statistical significance of the results (α = 0.05) (Demsar 
2006). In order to evaluate early enrichment in this study, 
enrichment factors at the top 1% of the hit-list (EF1) were 
calculated. Since the top 1% of the “own decoys” set is smaller 
than the number of active compounds, only the enrichment 
factors for the “combined decoys” set are presented. 
Perhaps more importantly than just producing simple 
enrichment is that virtual screening should reveal unique 
chemical structures for lead discovery i.e. be able to do scaffold 
hopping. However, as the ligands in the data set were not 
clustered, this kind of analysis was not feasible. The 
classification of Good cannot be applied here, as it is intended 
for a filtered subset of the original DUD. 
FieldChopper ROC AUC averages were quite similar with both 
BRUTUS and ROCS superimpositions, even though there is a 
statistically significant difference in the combined decoys set 
(Table 5.10). The difference in FieldChopper’s accuracy between 
the two algorithms could be explained by the fact that BRUTUS 
was used to produce the alignments for the models. It seems 
that FieldChopper could be used with both methods. This is not 
surprising, since both methods have been shown to produce 
reasonable molecular alignments. 
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Table 5.10: FieldChopper ROC AUCs with alignments from BRUTUS and ROCS. 
Wilcoxon signed pairs test: combined decoys set P = 0.01 < 0.05, own decoys set P = 
0.5186 > 0.05. 
 FieldChopper(combined) FieldChopper (own) 
Target BRUTUS ROCS BRUTUS ROCS 
ACHE 0.874 0.863 0.516 0.567 
AR 0.930 0.898 0.803 0.810 
COX2 0.909 0.867 0.896 0.891 
DHFR 0.860 0.939 0.830 0.957 
EGFR 0.822 0.732 0.798 0.777 
ERagonist 0.933 0.915 0.775 0.767 
FGFR1 0.620 0.472 0.585 0.515 
FXA 0.928 0.868 0.915 0.906 
GR 0.912 0.627 0.814 0.594 
INHA 0.804 0.767 0.832 0.826 
P38 0.777 0.740 0.735 0.801 
SRC 0.640 0.513 0.702 0.644 
mean 0.834 0.767 0.767 0.755 
median 0.867 0.815 0.801 0.789 
 
ROC curves for EON and FC sets are shown in Figures 5.3 and 
5.4. The early enrichment measured by enrichment factors at 1% 
(EF1) of a ranked database for FieldChopper and EON are 
shown in Tables 5.11 and 5.12. Both methods displayed a similar 
overall performance when one examines average and median. 
FieldChopper outperformed EON on nuclear hormone targets 
(AR, ERagonist, and GR), whereas EON exhibited higher 
enrichment on ACHE and INHA. There was high enrichment on 
COX2, which was also reported in the previous study on EON 
by Nicholls and co-workers (Nicholls et al. 2004). The huge 
difference in performance on FXA is caused by the bias in DUD. 
As the ligands are charged differently than the decoys, 
FieldChopper can easily distinguish the ligands and decoys due 
to the charge alone. 
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Table 5.11: ROC AUCs for FieldChopper and EON. FieldChopper outperforms EON 
in both data sets (Wilcoxon signed rank test: combined decoys P = 0.001465 < 0.05, 
own decoys P = 0.02100 < 0.05). 
 combined own 
Target FieldChopper EON FieldChopper EON 
ACHE 0.516 0.778 0.874 0.910 
AR 0.803 0.676 0.930 0.677 
COX2 0.896 0.884 0.909 0.878 
DHFR 0.830 0.769 0.860 0.767 
EGFR 0.798 0.702 0.822 0.713 
ERagonist 0.775 0.619 0.933 0.739 
FGFR1 0.585 0.456 0.620 0.298 
FXA 0.915 0.399 0.928 0.249 
GR 0.814 0.725 0.912 0.593 
INHA 0.832 0.758 0.804 0.715 
P38 0.735 0.596 0.777 0.572 
SRC 0.702 0.292 0.640 0.338 
mean 0.767 0.638 0.834 0.621 
median 0.801 0.689 0.867 0.695 
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Table 5.12: : Enrichment Factors at 1% of Ranked Database. Both methods have 
similar overall performance. FieldChopper outperforms EON on nuclear hormone 
targets (AR, ERagonist, and GR), while EON has a higher enrichment factor on ACHE 
and INHA. The maximum enrichment factor is 100. 
 combined 
Target FieldChopper EON 
ACHE 39.79 64.47 
AR 66.19 64.47 
COX2 54.41 45.69 
DHFR 1.08 3.76 
EGFR 9.10 10.73 
ERagonist 61.62 28.88 
FGFR1 0.00 0.00 
FXA 4.73 0.79 
GR 30.20 6.36 
INHA 11.43 28.57 
P38 0.42 3.32 
SRC 0.72 4.29 
mean 23.14 18.10 
median 10.26 8.55 
. 
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Figure 5.3: ROC curves for the own set. FieldChopper (solid line) outperforms EON 
(dotted line) in most cases. (1 of 2) 
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Figure 5.3: ROC curves for the own set. FieldChopper (solid line) outperforms EON 
(dotted line) in most cases. (2 of 2) 
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Figure 5.4: ROC curves for the combined set. FieldChopper (solid line) outperforms 
EON (dotted line) on most cases. (1 of 2) 
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Figure 5.4: ROC curves for the combined set. FieldChopper (solid line) outperforms 
EON (dotted line) in most cases. (2 of 2) 
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6 The effect of 
tautomerism and 
protonation on SBVS 
As tautomerism and ionization may significantly change the 
interaction possibilities between a ligand and a target protein, 
these phenomena could have an effect on structure-based 
virtual screening. However, there is very little information 
published on the effect of tautomeric and protonation state 
enumeration on the enrichment of active molecules in structure-
based virtual screening. In this next chapter, the impact of this 
database preparation step is examined with retrospective virtual 
screening. The chapter is adapted with permissions from: 
Kalliokoski T, Salo HS, Lahtela-Kakkonen M, Poso A: The Effect 
of Ligand-Based Tautomer and Protomer Prediction on 
Structure-Based Virtual Screening. Journal of Chemical 
Information and Modeling 49: 2742-2748, 2009. Copyright © 
2009 American Chemical Society. 
6.1 INTRODUCTION 
From the computational point of view, the different tautomers 
of the same compound are all different molecules. Tautomeric 
and protonation-state enumeration ensures that the state with 
optimal interaction possibilities is always included in the 
screening process, as the predicted state may not always be the 
optimal binder. However, the enumeration of all possible forms 
of a compound increases the computing time considerably with 
larger data sets as a significant proportion of molecules in 
chemical vendor databases are tautomeric. Milletti and co-
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workers analyzed four chemical databases containing 683,862 
molecules for tautomerism from which 29% were tautomeric 
(Milletti et al. 2009). 
In addition to tautomerism, protonation and ionization affect 
many drug molecules since many are either weak acids or bases. 
Predicting the correct protonation state (protomer) for a 
molecule is also not straightforward, as it requires estimation of 
pKa-values of acidic and basic functional groups in the 
molecule.  
An alternative to enumeration is to predict the most likely 
tautomeric form a molecule and to discard the other forms (see 
Chapter 2.5). The effect of the prediction of tautomers and 
protomers in the virtual screening context has been surprisingly 
little studied. Several articles emphasize the importance of 
tautomers (Pospisil et al. 2003; Kirchmair et al. 2008; Martin 
2009), but there are only a few studies where the effect of 
tautomerism on SBVS has been explicitly studied. Knox and co-
workers studied the impact of various aspects of database 
preprocessing to SBVS using ER-alpha antagonists as the target 
(Knox et al. 2005). They concluded that the enumeration of 
tautomers increased the number of false positive compounds. 
That study, as well as the other studies on tautomerism and 
SBVS, suffers from the small data set: only one target was used 
to study the phenomena. The performance of a docking 
program is however highly dependent on the target protein 
(Cross et al. 2009) and thus general conclusions can only be 
made from a diverse set of proteins. Polgár and co-workers 
studied the effect of ligand protonation with beta-secretase 
BACE1 using several docking programs (Polgár et al. 2007). 
Their conclusion was that consideration of all possible 
protomers does not necessarily increase screening efficiency and 
may be just a waste of computing resources. During the 
preparation of this thesis, ten Brink and Exner published a study 
on the influence of protonation, tautomeric, and stereoisomeric 
states on SBVS (ten Brink and Exner 2009). Their data set was 
also rather limited as well; only 15 active ligands seeded with 
735 properties matched decoys from ZINC. It was suggested 
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that enumeration of different forms was detrimental to the 
screening performance due to the creation of unreasonable 
protonation states.  
This present study is the first to investigate the issue of different 
tautomeric and protonation states in SBVS using a diverse, 
publicly available data set. 
6.2 PREPARATION OF THE DATA SET 
6.2.1 Target Selection and Protein Structure Preparation 
From the 40 targets in the original DUD data set, a subset of 28 
proteins was initially selected for this study. Metalloproteins as 
a group were excluded from this study, since for these targets, 
the binding site’s microenvironment for a ligand is clearly 
different from that of a solution or vacuum due to the presence 
of the metal ion (Pospisil et al. 2003; ten Brink and Exner 2009). 
No ligand-based tautomerism and protonation prediction 
method can make sensible predictions without taking into 
account the interaction of the protein with these targets. The 
current version of MoKa does not provide a solution for this 
problem, and thus, metalloproteins are clearly beyond the scope 
of this investigation. Other structures that were excluded 
displayed problems with the crystal structures, such as 
broken/missing ligands (CDK2, VEGFR2, HIVPR), covalent 
ligand binding (thrombin), or missing experimental details 
(DHFR, TK). There was also one homology model in the DUD 
data set (PDGFRB), which was removed from the data set.  
Protein structures were downloaded from the DUD Web site 
(http://dud.docking.org, accessed June 1, 2009). The structures 
were used as is, except for the addition of hydrogen atoms with 
the Protonate3D method implemented in MOE (Labute 2009). 
The temperature and pH parameters for Protonate3D were 
taken from the PDB file (values from the crystallization process). 
Protonate3D is a method for predicting hydrogen geometry, 
ionization, and tautomeric states of macromolecular structures. 
It uses a unary quadratic optimization algorithm to optimize the 
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Gibbs energy of the system and to find the optimal 
configuration of all possible tautomeric and ionization states. 
The energy model used in the optimization includes van der 
Waals, Coulomb, solvation, rotamer, tautomer, and titration 
effects. 
6.2.2 Ligand and Decoy Molecule Preparation 
The molecular databases used in this study were built using the 
DUD. As DUD ligands and decoys suffer from an imbalance 
between charged molecules (42% ligands are charged, as 
compared to 15% of decoys), only molecules that had multiple 
forms in the MoKa suite were selected for this study (Irwin 
2008). It was also expected that the effect of tautomer and 
protomer enumeration would be more clearly visible in this 
way. The disadvantage of this procedure was that it made it 
impossible to compare the results directly to other SBVS studies 
conducted on the DUD data set. 
Ligands and decoys were downloaded in single enantiomer 
SMILES format from the ZINC database (http://zinc.docking. 
org, accessed June 10, 2009) (Irwin and Schoichet 2005). Two sets 
of molecules were generated using the MoKa suite version 1.10 
(Molecular Discovery Ltd). The enumerated set contained all of 
the tautomeric and protonation states, whereas the predicted set 
included only a single form for each compound. The pH values 
for the MoKa predictions were taken from the PDB files. The 
initial three-dimensional (3D) conformations for the docking 
were calculated using CORINA version 3.20 (Molecular 
Networks GmBH). 
6.3 THE DOCKING PROTOCOL 
The AutoDock version 4.0 was used for docking (Huey et al. 
2004; Huey et al. 2007). The program is widely used in docking 
studies and can also be utilized for virtual screening, provided 
that supercomputing resources are available (Park et al. 2006; 
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Jacq et al. 2008; Trott and Olson 2010). AutoDock is described in 
Chapter 2.4. 
AutoDock is computationally exceedingly demanding for 
virtual screening of larger databases and, thus, requires 
extensive supercomputing resources. However, it is the only 
GNU General Public License (GPL) licensed docking program 
currently available. The license allows its use on both academic 
and commercial projects without limitations or fees. 
Proteins and small molecules were prepared for docking with 
AutoDockTools version 1.5.4 (Sanner 1999). The docking grid 
was centered on the cocrystallized ligand, and default values 
were used for docking.  
In order to validate the docking procedure, the cocrystallized 
ligand was redocked in a MoKa predicted form, and the RMSD 
between the docked and crystallized pose was calculated. The 
validation dockings were performed twice, since AutoDock uses 
a genetic algorithm which is prone to problems with sampling 
(ten Brink and Exner 2009). Targets that were not correctly 
docked were removed from the virtual screening phase. The 
limit for RMSD was set to 2 Å (Warren et al. 2006; Watts et al. 
2010) and no significant difference between the two runs was 
allowed.  
The results from the crystal structure dockings are presented in 
Table 6.1. The RMSDs of protein-ligand complexes for ACHE, 
AMPC, EGFR, FXA, HSP90, PARP, PPARG and trypsin were 
over 2 Å. GPB could not be reliably docked, as there was almost 
a 2 Å difference between the two runs. These targets were 
removed from the virtual screening phase. A total of 19 targets 
were selected for the SBVS phase. 
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Table 6.1: Root-Mean-Square Deviations (RMSD, Å) and Highest Ranking Energies 
(kcal/mol) from the docking validation step. The removal criteria values are in italics. 
Target RMSD (Å) energy 
(kcal/
mol) 
ΔRMSD (Å) Δenergy 
(kcal/mol) 
ACHE 4.44 -10.32 1.84 0.41 
ALR2 0.54 -7.52 0.68 0.20 
AMPC 2.09 -7.41 0.93 0.14 
AR 0.47 -10.60 0.04 0.00 
COX1 0.70 -8.31 0.17 0.01 
COX2 1.39 -10.24 0.13 0.02 
EGFR 3.56 -6.52 1.88 0.37 
ERagonist 0.70 -10.85 0.12 0.04 
ERantagonist 1.25 -13.10 0.28 0.14 
FGFR1 0.97 -7.05 0.04 0.07 
FXA 2.13 -10.11 0.33 0.91 
GART 1.54 -11.57 0.03 0.45 
GPB 0.62 -7.01 1.99 0.10 
GR 0.78 -11.12 0.06 0.02 
HIVRT 0.44 -9.00 0.33 0.02 
HMGR 1.44 -8.34 0.08 0.42 
HSP90 4.60 -7.12 1.81 0.03 
INHA 0.47 -11.98 0.09 0.11 
MR 0.58 -12.09 0.02 0.11 
NA 1.89 -13.00 0.07 0.12 
P38 0.95 -13.84 0.09 0.17 
PARP 2.04 -8.20 0.01 0.04 
PNP 0.42 -10.87 0.02 0.01 
PPARG 2.75 -10.34 0.26 1.19 
PR 0.87 -13.36 0.13 0.04 
RXRA 0.75 -14.04 0.02 0.02 
SAHH 0.65 -8.13 0.06 0.06 
Trypsin 2.52 -6.88 1.84 0.09 
. 
ten Brink and Exner have previously discussed  the effect of 
different protonated, tautomeric, and stereoisomeric forms on 
the pose prediction, using the high-quality CCDC/ ASTEX data 
set, thus the focus of this study was to evaluate enrichment on 
SBVS and therefore, the redocking results were not analyzed. 
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The issues relating to the SBVS have been discussed on Chapter 
2.6. 
6.4 RETROSPECTIVE VIRTUAL SCREENING 
The docking time per molecule was limited in order to keep the 
computational time feasible. The maximum time allowed was 
double the time used for the cocrystallized ligand. If the 
molecule was not docked within the time limit, then it was 
removed from the assessment. Each molecule was docked 10 
times to the protein, and the highest ranked pose (the one with 
the lowest energy) was used in the final hit list. For the 
predicted data set, only the predicted form was used. The 
dockings were calculated using a 2176 CPU Linux cluster. The 
numbers of molecules docked are shown in Table 6.2. 
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Table 6.2: Data Sets Used in Virtual Screening Experiments. Nlig is the number of 
ligand compounds, Ndec is the number of decoy compounds, Dlig is the number of 
different ligand forms docked, Ddec is the number of different decoy forms docked, Fenum 
is the fraction of ligands in the numerated set, and Fpred is the fraction of ligands in the 
predicted set 
Target pH T (K) Nlig Ndec Dlig Ddec Fen
% 
Fpr  
% 
ALR2 6.2 273 19 677 127 4168 3.1 2.8 
AR 7.9 93 63 2234 548 14465 3.8 2.8 
COX1 6.7 180 6 280 22 1180 1.9 2.1 
COX2 8.0 113 189 9174 610 48140 1.3 2.1 
ERagonist 8.8 103 62 1695 278 11004 2.5 3.7 
ERantagonist 7.0 100 16 896 69 3746 1.8 1.8 
FGFR1 6.5 110 107 3313 2383 31659 7.5 3.2 
GART 7.2 94 12 195 792 13775 5.8 6.2 
GR 8.0 100 67 2241 302 9834 3.1 3.0 
HIVRT 5.0 100 35 1083 197 6685 3.0 3.2 
HMGR 7.5 123 31 994 130 8337 1.6 3.1 
INHA 6.8 120 70 2450 279 14897 1.9 2.9 
MR 7.5 100 13 467 283 4366 6.5 2.8 
NA 7.8 100 48 1308 251 14066 1.8 3.7 
P38 7.4 100 230 6801 2271 45532 5.0 3.4 
PNP 8.0 140 22 639 834 18221 4.6 3.4 
PR 6.5 100 27 835 99 3570 2.8 3.2 
RXRA 7.0 93 18 463 57 2480 2.3 3.9 
SAHH 5.6 100 31 817 521 21343 2.4 3.8 
. 
The SBVS results were evaluated using two commonly used 
metrics: Enrichment factor (EF) and ROC AUC. ROC AUCs 
were calculated using ROCR (Sing et al. 2006). As there are 
relatively few decoys per ligand in the data set, the cutoff of 5% 
was selected as the enrichment factor. This means that the 
maximum enrichment factor is 20. 
The enrichment metrics are shown in Table 6.3, and the ROC 
curves are shown in Figure 6.1. There is no major difference 
between the enumerated and the predicted sets in terms of the 
enrichment metrics. This finding is in line with the previous 
SBVS studies on the effect of tautomerism and protonation that 
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used single targets (Pólgar et al. 2007; ten Brink and Exner 2009). 
However, there is a vast difference in computing time per 
compound. With a rather slow docking method, like AutoDock, 
the extra time spent in considering the enumerated tautomers 
and protomers becomes quickly very significant. The 
enumeration can also be an issue with large databases 
incorporating millions of compounds. Therefore, the use of a 
single, reasonable form of the molecule for structure-based 
virtual screening of molecular databases is recommended. 
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Table 6.3: ROC AUCs, EFs at 5% (EF5) and Mean Times Per Compound Used in 
minutes (t) for Docking Shown for the Enumerated and the Predicted Set. There is no 
statistical difference (as measured by Wilcoxon signed rank test) between ROC AUCs 
between the two sets (Demsar 2006). *=For GART, 255 runs was also used instead of 
the standard 10, illustrates the sampling problem. 
 Enumerated set Predicted set 
Target ROC 
AUC 
EF5 t ROC 
AUC 
EF5 t 
ALR2 0.516 1.05 50 0.538 3.14 8 
AR 0.712 4.44 46 0.719 4.12 8 
COX1 0.390 3.41 36 0.334 0 8 
COX2 0.851 8.36 52 0.877 9.95 10 
ERagonist 0.868 10.95 50 0.883 10.63 8 
ERantagonist 0.862 16.11 59 0.841 14.87 14 
FGFR1 0.321 1.12 132 0.381 1.12 14 
GART* 0.881 6.90 793 
0.639/ 
0.859 
5.18/
10.35 
17/ 
690 
GR 0.598 4.19 38 0.647 5.09 10 
HIVRT 0.363 2.28 55 0.395 1.71 9 
HMGR 0.886 5.84 106 0.829 5.19 13 
INHA 0.389 4.57 65 0.423 4.57 11 
MR 0.845 3.08 87 0.765 0 9 
NA 0.838 7.48 107 0.843 8.31 10 
P38 0.585 3.21 73 0.554 1.65 11 
PNP 0.528 4.55 248 0.516 4.55 9 
PR 0.630 7.43 36 0.634 5.20 9 
RXRA 0.969 11.13 65 0.967 11.13 12 
SAHH 0.418 0 216 0.548 0.65 9 
mean 0.655 5.58 122 0.649 5.11 11 
median 0.630 4.55 65 0.639 4.57 10 
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Figure 6.1: ROC curves for the enumerated (solid line) and predicted (dotted line) sets. 
For GART, the predicted set performance increased significantly (dashed line) with 
increased sampling. (1 of 4) 
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Figure 6.1: ROC curves for the enumerated (solid line) and predicted (dotted line) sets. 
For GART, the predicted set performance increased significantly (dashed line) with 
increased sampling. (2 of 4) 
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Figure 6.1: ROC curves for the enumerated (solid line) and predicted (dotted line) sets. 
For GART, the predicted set performance increased significantly (dashed line) with 
increased sampling. (3 of 4) 
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Figure 6.1: ROC curves for the enumerated (solid line) and predicted (dotted line) sets. 
For GART, the predicted set performance increased significantly (dashed line) with 
increased sampling. (4 of 4) 
 
There is a striking difference between the enumerated and the 
predicted set on GART. The potential reasons for this are 
inadequate sampling and exceptionally large numbers of 
different tautomers and protomers per compound on this target. 
In order to determine if this is really the case, the predicted set 
was redocked with an increased number of docking runs. The 
number of LGA runs was increased from 10 to 255. The ROC 
AUC of the predicted set rose from 0.639 to 0.859, which is much 
closer to the ROC AUC of the enumerated set (0.881). The 
enumerated set was not redocked with the new settings because 
this would have been computationally extremely demanding, 
requiring approximately 18 CPU years. 
Even though the data set used here is not the DUD itself, some 
rough comparisons can be made to other benchmarking studies 
which have utilized DUD. Cross and co-workers compared 
several commonly used docking methods with the whole 40 
protein data set from the DUD (Cross et al. 2009). The mean 
ROC AUC values for the whole 40 protein data set varied from 
0.55 to 0.77, depending on the docking method. As the mean 
ROC AUC for the data sets in this study is approximately 0.65, 
AutoDock’s performance seems to be typical for a docking 
program. There are 9 cases out of 19 where clear enrichment can 
be seen (ROC AUC > 0.70). ER, NA and RXRA have been shown 
previously to represent easy targets for docking programs, 
whereas the kinase targets FGFR1 and P38 are very challenging 
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for the current docking programs (Huang et al. 2006; Cross et al. 
2009). 
It has been suggested that the number of false positives may 
increase on the enumerated set due to the strongly charged and 
unlikely forms of decoy molecules that receive high scores (ten 
Brink and Exner 2009). The mean energies for ligands and 
decoys were calculated to verify this assumption (Table 6.4). It 
can be seen that the energy difference is usually larger for the 
decoys between the enumerated and the predicted sets than 
with that of ligands. The effect is more clearly visible on those 
targets where there is good enrichment (ERagonist, ERantagonist, 
COX2, GART, and RXRA).  However, this change in the energy 
differences is so small that it does not translate into any major 
differences between the ROC AUC values of the two sets. 
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Table 6.4: Average Energies from Docking Results. *=the predicted data set energies 
are from the 255 LGA run. 
 Enumerated set Predicted set   
Target Elig Edec Elig Edec ΔElig ΔEdec 
ALR2 -7.35 -7.53 -6.99 -7.07 0.36 0.46 
AR -9.44 -8.40 -9.08 -7.83 0.36 0.57 
COX1 -7.05 -7.42 -6.66 -7.18 0.39 0.24 
COX2 -9.79 -8.54 -9.60 -8.07 0.19 0.47 
ERagonist -8.63 -7.50 -8.35 -7.07 0.28 0.43 
ERantagonist -11.58 -9.32 -11.26 -8.83 0.32 0.49 
FGFR1 -7.20 -7.59 -6.47 -6.77 0.73 0.82 
GART* -11.33 -8.96 -11.54 -8.61 0.24 0.35 
GR -9.34 -8.79 -9.07 -8.34 0.27 0.45 
HIVRT -8.68 -8.96 -8.09 -8.39 0.59 0.57 
HMGR -7.96 -6.63 -7.19 -6.01 0.77 0.62 
INHA -8.67 -8.86 -8.43 -8.46 0.24 0.45 
MR -10.37 -8.91 -9.42 -8.46 0.95 0.40 
NA -8.43 -6.78 -7.87 -6.04 0.56 0.74 
P38 -9.78 -9.52 -9.26 -9.05 0.52 0.47 
PNP -7.56 -7.49 -6.83 -6.70 0.73 0.79 
PR -8.95 -8.34 -8.65 -8.03 0.30 0.31 
RXRA -12.20 -8.64 -11.98 -8.23 0.22 0.41 
SAHH -7.19 -7.57 -6.26 -6.03 0.93 1.54 
mean -9.03 -8.20 -8.38 -7.54 0.47 0.56 
median -8.68 -8.40 -8.35 -7.83 0.36 0.47 
 
As revealed in the study of Warren and co-workers (Warren et 
al. 2006), the docking programs may be capable of reproducing 
crystal structures and identifying active molecules from a pool 
of inactive molecules, but they are not able to rank properly 
closely related molecules. Tautomers and protomers of a 
molecule can be considered as closely related molecules from 
the docking program’s point of view. The accuracy of the 
scoring functions might not be sufficient to separate different 
tautomers and protomers in virtual screening programs. 
Todorov and co-workers studied the dependence of docking 
results on the tautomeric and protonation states of the ligand on 
three protein-ligand complexes (Todorov et al. 2006). The 
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differences in the protonation pattern occurred at positions 
where they only had a limited impact on the binding energy, 
and also the flexible bonding groups permitted a greater 
number of hydrogen bonds to be formed than were found in the 
crystal structures. It was concluded that ligand binding is rather 
insensitive to changes in the tautomeric and protonation states. 
This could also explain the small difference between the 
enumerated and the predicted set observed in this study. 
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7 GPUs and single 
conformation databases in 
LBVS 
Recently, a GPU-version called PAPER of widely-used ROCS 
algorithm was published (Paque and Hande 2010). In order to 
study the applicability of the PAPER algorithm to ligand-based 
virtual screening, a command line interface for the PAPER 
algorithm intended to facilitate virtual screening was developed 
and the effect of conformation analysis of both query and 
database molecules was investigated. The chapter is based on 
the following publication: Kalliokoski T, Rönkkö T, Poso A: 
Increasing the throughput of shape-based virtual screening with 
GPU processing and single conformation databases. Molecular 
Informatics 29: 293-296, 2010. Copyright Wiley-VCH Verlag 
GmbH & Co. KGaA. Reproduced with permission. 
7.1 INTRODUCTION 
Shape-based virtual screening is based on the ranking of 
molecules according to their shape similarity (see Chapter 2.3.2). 
As small molecules are typically flexible and can adopt several 
conformations, conformational analysis is required before the 
screening process. Usually a single conformation that is 
assumed to be the “bioactive” conformation i.e. the 
conformation observed in the protein-ligand crystal complex is 
used for the query, whereas a conformational ensemble is 
created for the database molecules. There are several arguments 
why this might not be the optimal approach for shape-based 
virtual screening. The use of an in silico conformation instead of 
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one from an X-ray crystallography model has been shown to 
produce equal results (Hawkins et al. 2007). However, as 
ligands and proteins are usually rather flexible structures, they 
often have several possible conformations and there is no simple 
way to say which of the conformations are bioactive from all the 
possibilities (Borodina et al. 2007; Watts et al. 2010). It is 
therefore reasonable to propose that multiple conformations for 
the query molecule could improve the results as the risk of 
overlooking the bioactive conformation would be decreased. On 
the other hand, virtual screening is simply similarity searching. 
The task is to find molecules that are similar to the query, not to 
predict how they might bind to the target protein. The use of 
single conformation databases might be also therefore feasible.  
Given that shape-based virtual screening is widely used in 
industry and academia, the effect of different conformational 
analysis approaches on accuracy has been surprisingly little 
studied. Tawa and co-workers proposed technique called 
CORAL (Conformational analysis, Rocs Alignment) (Tawa et al. 
2009). It is based on the assumption that the ligands share the 
same conformational space, which contains the bioactive 
conformations. This is illustrated in Figure 7.1, where the five 
compounds have different individual conformations, but they 
share the bioactive conformation space. 
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Figure 7.1: The idea of CORAL (adapted from Tawa et al. 2009). 
 
CORAL requires multiple known ligands. First, a 
conformational expansion of each ligand is performed. It is 
assumed that all ligands share the same binding mode. Then, 
every conformation of every ligand is superimposed with each 
other to form matrix O of the similarity scores: 
 
ܱ ൌ ൦
ͳ ܱଵଶ ǥ ܱଵ௝
ܱଶଵ ͳ ǥ ܱଶ௝
ǥ ǥ ǥ ǥ
ܱ௜ଵ ܱ௜ଶ ǥ ͳ
൪ 
 
where the Oij is the similarity score (see Chapter 2.3.4) with 
between conformations i and j. Vector A is calculated from 
matrix O by averaging every row: 
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where N is the total number of conformations. CORAL query 
with index iCORAL is identified from vector A: 
 
݅஼ைோ஺௅ ൌ ሾܣሿ 
 
The authors of CORAL compared the virtual screening 
performance of ROCS with minimum energy conformation 
against CORAL conformation using DUD as the data set. It was 
concluded that using CORAL conformation instead of minimum 
energy conformation could be beneficial, as, on average, ROC 
AUC increased from 0.835 to 0.842. The obvious disadvantage of 
CORAL is that it requires multiple known ligands that are 
assumed to bind in exactly same binding mode. When using 
each ligand separately as a single query, this assumption is not 
required and as since shape based virtual screening is quite fast, 
it is not computationally prohibitive strategy either. As an 
example, the 15 actives used in FieldChopper models were used 
as queries for EON and superior enrichments were observed 
compared to the single query results (Table 7.1). 
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Table 7.1: ROC AUCs for EON with 15 query molecules per target using the datasets 
from the FieldChopper study. 
Target ROC AUC 
ACHE 0.827 
AR 0.912 
COX2 0.968 
DHFR 0.977 
EGFR 0.922 
ERagonist 0.905 
FGFR1 0.972 
FXA 0.930 
GR 0.976 
INHA 0.942 
P38 0.981 
SRC 0.906 
mean 0.935 
median 0.936 
 
Also, if one assumes that several ligands can be superimposed 
meaningfully, then one could also use pharmacophore methods 
and overcome the limitations of total similarity scoring. 
Kirchmair and co-workers studied the effect of using 
conformational ensembles as queries using ROCS and the DUD 
data set (Kirchmair et al. 2009).  In this approach, all 
conformations of the query molecule are scored against the 
database molecule and the highest scored pair is retained. The 
40 targets in DUD were screened using the PDB co-crystallized 
ligand as the query molecule. One, three, five and ten 
conformations were used for each query molecule. It was 
concluded that the use of multiple query conformations did not 
increase the virtual screening accuracy of ROCS significantly, as 
the average ROC AUCs for the screens with different number of 
query conformations increased from 0.72 to 0.74. However, this 
study has some issues. Firstly, the use of fixed numbers of query 
conformations between one and ten for all query molecules is 
problematic, as the number of reasonable and diverse 
conformations per molecule is clearly different. This can be seen 
from the number of conformations generated by ConfGen using 
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the FAST-setting (see Chapter 2.5.3 for details).  As illustrated in 
Figure 7.2, for half of the queries, ten conformations per 
molecule might not be enough, while 25% of query molecules 
have less than ten reasonable conformations. This leads to 
situation where in most cases, the number of conformations for 
the query molecule might not optimal. One should use all of the 
query’s conformations and not use arbitrary cutoffs. Secondly, 
the query molecule from the PDB crystal structure in some cases 
produces extremely poor ROC AUC, which is related to the data 
set composition: the query is simply too different from the 
ligands. In such cases, it is unreasonable to expect the use of 
multiple query conformations to overcome this fundamental 
limitation of LBVS (see Chapter 2.6). It would be better to use all 
of the ligands as a query instead using just a single molecule 
when analyzing the effect of the number of query’s 
conformations. Obviously, addressing these two issues would 
increase the computing time considerably and supercomputing 
facilities would be required. 
There is also the question of whether or not the use of multiple 
conformations for the database molecules increases the accuracy 
of virtual screening. The use of single conformation databases 
would significantly reduce the computing time and permit the 
screening of larger databases compared to the multi-
conformation databases. This strategy has not been studied on 
shape-based virtual screening, but Renner and co-workers have 
compared single and multi-conformation databases with 
CATS3D descriptors (Renner et al. 2006). In their study, the use 
of multi-conformation database only slightly improved the 
virtual screening performance and therefore the extra effort of 
conformational analysis was not justified. 
1
2
1
 
  
 
 
 
F
ig
u
re
 7
.2
: T
he
 n
u
m
be
r 
of
 d
iv
er
se
 c
on
fo
rm
at
io
n
s 
fo
r 
th
e 
qu
er
ie
s 
u
se
d 
in
 t
he
 K
ir
ch
m
ai
r 
st
u
dy
. T
he
 h
or
iz
on
ta
l 
li
n
es
 a
re
 t
he
 s
el
ec
te
d 
cu
to
ff
s 
fo
r 
th
e 
n
u
m
be
r 
of
 c
on
fo
rm
at
io
n
s 
u
se
d
 i
n
 t
h
e 
sc
re
en
in
g
. 
C
on
fo
rm
at
io
n
s 
w
er
e 
g
en
er
at
ed
 w
it
h
 C
on
fG
en
 u
si
n
g
 t
h
e 
‘F
A
S
T
’ 
p
re
se
t 
(S
ch
rö
d
in
g
er
 I
n
c)
.
0
1
0
2
0
3
0
4
0
5
0
6
0
7
0
8
0
9
0
ace
ache
ada
alr2
ampc
ar
cdk2
comt
cox1
cox2
dhfr
egfr
er_agonist
er_antagonist
fgfr1
fxa
gart
gpb
gr
hivpr
hivrt
hmga
hsp90
inha
mr
na
parp
pde5
pdgfrb
pnp
ppar
pr
p38
rxr
sahh
src
thrombin
tk
trypsin
vegfr2
122 
 
  
 
7.2 DEVELOPMENT OF COMMAND-LINE INTERFACE FOR 
PAPER 
Even though the source code for PAPER is freely available, the 
available version is not directly suitable for virtual screening, as 
it only outputs a 4x4 transformation matrix and does not handle 
multiple molecules.  Therefore, a user interface is required 
before the algorithm can be used for virtual screening. 
The PAPER GPU kernel was wrapped into a command-line 
interface named WeedyControl for PAPER (WCPAPER) without 
modifying the algorithm itself at all and by using as much as 
possible of the OpenBabel library. The simplified flowchart of 
the program is shown at Figure 7.3. First, the query molecule is 
loaded into RAM. Since the memory capacity varies between 
different GPU hardware, there is an adjustable parameter 
GPU_MOLS, which controls the number of molecules kept in 
VRAM at one time. After the template and database molecules 
have been read into VRAM, the molecules are aligned with 
PAPER. The overlap volumes and transformation matrices are 
copied from VRAM to RAM for similarity scoring and optional 
alignment output. ShapeTanimoto similarity S between 
molecules A and B is calculated from (Haque and Pande 2010): 
 
ܵ ൌ ஺ܱ஻
ሺ ஺ܱ஺ െ ܱ஻஻ ൅ ஺ܱ஻ሻ
 
 
where Oxy is the overlap volume between molecules x and y, 
calculated by PAPER using a spherical Gaussian function. The 
4x4 transformation matrix M generated by PAPER contains both 
the translation and rotation (Haque and Pande 2010): 
 
ܯ ൌ ൦
ݎଵଵ ݎଵଶ ݎଵଷ ݐ௫
ݎଶଵ ݎଶଶ ݎଶଷ ݐ௬
ݎଷଵ ݎଷଶ ݎଷଷ ݐ௭
Ͳ Ͳ Ͳ ͳ
൪ 
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Rotation matrix R and translation vector T are formed: 
 
ࡾ ൌ ൥
࢘૚૚ ࢘૚૛ ࢘૚૜
࢘૛૚ ࢘૛૛ ࢘૛૜
࢘૜૚ ࢘૜૛ ࢘૜૜
൩ 
 
ܶ ൌ ሾݐ௫ ݐ௬ ݐ௭ሿ 
 
Matrix R and vector T are applied to every atom of the molecule 
using OpenBabel by first applying Rotate()-function and then 
the Translate()-function in OBMol-class. Finally, the 
ShapeTanimoto scores and aligned molecules are outputted. 
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Figure 7.3: Simplified flowchart of WCPAPER. 
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PAPER algorithm assumes that molecules have been previously 
oriented by the singular value decomposition of the point cloud 
made up of the atom centers. This SVD-based preprocessing 
step is handled externally in a Python script, as it is only 
required once for each of the database molecules. The script 
supplied with the public version of PAPER uses the commercial 
OEChem library. The code was modified to use OpenBabel 
instead.  
As the number of starting positions is directly linked to the 
execution time of optimization algorithm, a low number of 
diverse positions would be preferable. There are nine different 
modes implemented in the PAPER code with an increasing 
number of starting positions n, although only four of them are 
described in the publication (Table 7.2). The cyclic translations 
in modes seven and eight are determined by a procedure that 
first decomposes the molecule into cyclic and acyclic 
components. Then, the centroid of each cyclic component is 
used as a translational starting point. Mode 1 is used for the 
alignment process in WCPAPER, as was recommended for 
virtual screening applications by Haque and Pande. 
 
Table 7.2: Different initialization modes implemented in PAPER. The mode 1 is used 
in WCPAPER (the original mode proposed by Grant and co-workers). 
Mode n Description 
0 1 Inertial overlay 
1 4 Mode 0 + 180° degree rotations around each axis 
2 12 Mode 1 + 90° degree rotations around each axis 
3 68 
Mode 1 + moving the center of molecule of each molecule 
onto a corner of the bounding box of the other 
4 204 
Mode 2 + moving the center of molecule of each molecule 
onto a corner of the bounding box of the other 
5 30 30 random orientations 
6 12 12 random orientations 
7 4*RS 
180° degree rotations around each axis for each cyclic 
translation 
8 12*RS 
90° and 180°  degree rotations around each axis for each 
cyclic translation 
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In order to find the optimum for GPU_MOLS, COX2 data set 
was screened on two different computers with four different 
values (100, 1000, 5000 and 10000) using a typical query 
molecule with 22 heavy atoms (Table 7.3). The value of 1000 
seems optimal, as one must take into account the fact that some 
databases may have larger molecules that consume more 
memory than those in the COX2 data set. The value of 100 is 
recommended for graphics adapters with little memory, such as 
those found in laptop computers. 
 
Table 7.3: Running times in seconds for WCPAPER on two different systems and four 
GPU_MOLS values. There was not enough memory in 8800GT for 10000 molecules. 
OS=Operating System, GA=Graphics Adapter 
OS CPU GA Cores VRAM 100 1k 5k 10k 
Linux 
(CentOS 
5.4, 64bit) 
2.67 
Ghz 
Intel 
Core 
i5 
Nvidia 
GeForce 
295GTX 
2 x 
240 
2 x 
896 
MB 
273 158 158 159 
Mac OS X 
(10.6) 
2.8 
Ghz 
Intel 
Xeon 
Nvidia 
GeForce 
8800GT 
112 
512 
MB 
298 235 
 
230 
 
- 
 
CPU/GPU architecture, system libraries and compilers can 
influence virtual screening accuracy: sometimes even incorrect 
results are produced (Feher and Williams 2009). Since GPU 
computing has been only recently introduced and both 
hardware and software are changing very rapidly, it is likely 
that GPU applications will be especially vulnerable for such 
anomalies. The impact of the computing platform is visible on 
WCPAPER. The two different computers used in performance 
testing produced slightly different ShapeTanimoto values 
(Figure 7.4). Even though these differences are quite subtle, they 
clearly have an effect on the virtual screening performance 
(Figure 7.5). As the source code is exactly same in both cases, 
this difference originates from hardware, system software or 
compilers. It is therefore important to use the same platform in 
comparative studies. 
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Figure 7.4: The ShapeTanimoto values from two different computer platforms. Pearson 
correlation coefficient is 0.999481. 
 
 
Figure 7.5: ROC curves produced by the two computers. 
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7.3 PREPARATION OF THE DATA SET 
The data set used in this study was built from DUD LIB VS (see 
Chapter 3.1). The ligand and decoy molecules with just a single 
conformation were removed in order to amplify the effect of 
different conformational approaches. The number of 
conformations for the molecules is shown in Table 7.4. 
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Table 7.4: The number of molecules and conformations for each of the targets used in 
the study. 
Target S L LC C/L D DC C/D 
ACE 19 45 615 14 1722 25703 15 
ACHE 16 96 1458 15 3651 46685 13 
ADA 8 23 283 12 809 9483 12 
ALR2 13 21 123 6 847 6229 7 
AMPC 6 21 203 10 695 5136 7 
AR 6 37 163 4 2346 13590 6 
CDK2 31 46 431 9 1758 23900 14 
COMT 2 11 222 20 395 4122 10 
COX1 10 21 66 3 754 4189 6 
COX2 39 190 851 4 11375 105895 9 
DHFR 14 184 1383 8 7014 108543 15 
EGFR 40 348 2496 7 14297 164230 11 
ERagonist 10 60 275 5 2150 14874 7 
Erantagonist 8 18 317 18 1016 17401 17 
FGFR1 12 64 389 6 3186 61218 19 
FXA 19 64 1370 21 1883 44928 24 
GART 5 8 240 30 118 3641 31 
GPB 9 51 919 18 1824 27287 15 
GR 8 23 109 5 2233 14731 7 
HIVPR 3 4 73 18 9 253 28 
HIVRT 12 27 215 8 1388 13317 10 
HMGA 4 25 557 22 1192 22955 19 
HSP90 4 23 243 11 849 11475 14 
INHA 23 57 550 10 2436 24308 10 
MR 2 8 36 4 496 3525 7 
NA 7 49 402 8 1580 26406 17 
P38 19 114 862 8 5883 52815 9 
PARP 6 16 67 4 915 4550 5 
PDE5 21 25 163 7 1550 23591 15 
PDGFRB 21 102 627 6 5209 61716 12 
PNP 3 23 149 6 812 9050 11 
PPARG 6 6 97 16 38 716 19 
PR 3 19 60 3 772 4054 5 
RXRA 3 18 85 5 545 6077 11 
SAHH 2 33 390 12 1124 14393 13 
SRC 20 86 638 7 5206 86405 17 
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Thrombin 13 23 361 16 1059 27985 26 
TK 7 22 236 11 757 7373 10 
Trypsin 6 8 117 15 663 17795 27 
VEGFR2 25 40 408 10 2466 34805 14 
 
Four different conformational analysis approaches were 
investigated: single conformation query with single 
conformation database (SINGLE_SINGLE, SS), single 
conformation query with multi-conformation database 
(SINGLE_MULTI, SM), multi-conformation query with single 
conformation database (MULTI_SINGLE, MS) and multi-
conformation query with multi-conformation database 
(MULTI_MULTI, MM). From these, SINGLE_MULTI is the most 
commonly used methodology. Single conformations were 
generated with MacroModel version 9.7 using OPLS_2003 force-
field and multiple conformations were calculated with ConfGen 
version 2.1 using the ‘FAST’ preset and an energy cut-off of 
25kcal/mol was applied. 
7.4 RETROSPECTIVE VIRTUAL SCREENING 
Every ligand was used as a query one at a time for the 
screening. The query was removed from the ligands and the 
highest scored similarity value was used for each of the 
molecules in the database.  
ROC AUC values were used to measure the accuracy. As the 
ROC AUC measures overall performance and does not take into 
account the early enrichment or the chemical diversity of the hit 
molecules, the fractions of the possible scaffolds retrieved were 
also calculated (see Chapters 3.2 and 3.3). 
As the targets in DUD all have different molecules, the results 
were also analyzed by calculating median values for each of the 
targets. The median was used instead of average, because it was 
expected that there are some queries in every target that 
perform either exceptionally well or poorly compared to others. 
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Box plots of ROC AUCs of queries (Figure 7.6) and of target 
medians (Figure 7.7) show that the differences in screening 
accuracy between the conformational analysis approaches are 
negligible (the hinges in the figures are versions of the first and 
third quartiles). The values of different target ROC AUCs are 
shown in Table 7.5. 
 
 
Figure 7.6: Box plot of query ROC AUCs. 
 
 
Figure 7.7: Box plot of target median ROC AUC. 
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Table 7.5: Medians (Med) and averages (Avg) of target ROC AUCs. 
 SS SM MS MM 
Target Med Avg Med Avg Med Avg Med Avg 
ACE 0.52 0.47 0.67 0.48 0.47 0.45 0.46 0.45 
ACHE 0.69 0.64 0.75 0.68 0.71 0.64 0.73 0.66 
ADA 0.59 0.59 0.56 0.57 0.61 0.59 0.62 0.61 
ALR2 0.55 0.47 0.44 0.42 0.49 0.45 0.47 0.40 
AMPC 0.76 0.64 0.80 0.75 0.59 0.59 0.80 0.75 
AR 0.85 0.82 0.83 0.79 0.85 0.83 0.84 0.80 
CDK2 0.63 0.58 0.61 0.56 0.60 0.58 0.58 0.55 
COMT 0.60 0.51 0.58 0.50 0.60 0.49 0.59 0.49 
COX1 0.56 0.55 0.46 0.46 0.55 0.56 0.47 0.47 
COX2 0.90 0.86 0.88 0.81 0.93 0.88 0.91 0.84 
DHFR 0.66 0.65 0.68 0.67 0.74 0.73 0.80 0.77 
EGFR 0.70 0.67 0.67 0.62 0.73 0.69 0.70 0.65 
ERagonist 0.79 0.77 0.73 0.68 0.79 0.77 0.74 0.68 
ERantagonist 0.79 0.79 0.74 0.73 0.78 0.79 0.74 0.73 
FGFR1 0.76 0.68 0.62 0.57 0.76 0.69 0.63 0.58 
FXA 0.72 0.68 0.77 0.69 0.79 0.70 0.79 0.70 
GART 0.65 0.67 0.69 0.68 0.66 0.66 0.75 0.72 
GPB 0.76 0.66 0.75 0.66 0.75 0.65 0.75 0.64 
GR 0.75 0.72 0.70 0.64 0.75 0.70 0.68 0.63 
HIVPR 0.59 0.56 0.56 0.57 0.85 0.75 0.72 0.64 
HIVRT 0.46 0.49 0.54 0.52 0.49 0.49 0.54 0.51 
HMGA 0.61 0.60 0.63 0.62 0.67 0.64 0.74 0.70 
HSP90 0.74 0.73 0.72 0.71 0.76 0.76 0.69 0.72 
INHA 0.64 0.65 0.69 0.66 0.67 0.66 0.68 0.66 
MR 0.88 0.88 0.85 0.83 0.88 0.86 0.85 0.82 
NA 0.75 0.69 0.71 0.64 0.78 0.71 0.73 0.67 
P38 0.66 0.62 0.69 0.62 0.71 0.66 0.72 0.65 
PARP 0.54 0.53 0.55 0.55 0.54 0.53 0.57 0.57 
PDE5 0.83 0.79 0.82 0.74 0.88 0.83 0.85 0.78 
PDGFRB 0.72 0.70 0.63 0.61 0.71 0.68 0.62 0.60 
PNP 0.71 0.66 0.63 0.64 0.76 0.75 0.74 0.75 
PPARG 0.70 0.68 0.81 0.77 0.62 0.63 0.71 0.73 
PR 0.84 0.81 0.81 0.76 0.84 0.82 0.82 0.77 
RXRA 0.79 0.75 0.72 0.69 0.81 0.80 0.82 0.78 
SAHH 0.83 0.77 0.86 0.84 0.86 0.85 0.90 0.88 
SRC 0.64 0.66 0.54 0.55 0.69 0.68 0.57 0.58 
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Thrombin 0.72 0.67 0.62 0.62 0.70 0.64 0.66 0.61 
TK 0.57 0.53 0.64 0.63 0.60 0.58 0.63 0.62 
Trypsin 0.66 0.63 0.50 0.53 0.60 0.62 0.56 0.57 
VEGFR2 0.56 0.57 0.54 0.49 0.61 0.57 0.51 0.49 
average 0.69 0.66 0.52 0.64 0.70 0.67 0.69 0.66 
median 0.70 0.66 0.68 0.64 0.71 0.67 0.72 0.66 
 
As previously stated, the number of retrieved actives in the hit 
list is not as important in shape-based virtual screening as the 
chemical diversity of the top ranked compounds (Geppert et al. 
2010). All approaches yield the same chemical diversity of top 
hits (Figures 7.8 and 7.9, Table 7.6). 
 
 
Figure 7.8: Box plot of fraction of retrieved scaffolds. 
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Figure 7.9: Box plot of target median fraction of retrieved scaffolds. 
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Table 7.6: Medians (Med) and averages (Avg) of retrieved scaffolds. 
 SS SM MS MM 
Target Med Avg Med Avg Med Avg Med Avg 
ACE 0.16 0.17 0.16 0.16 0.16 0.16 0.16 0.15 
ACHE 0.25 0.25 0.31 0.29 0.31 0.29 0.31 0.29 
ADA 0.38 0.30 0.38 0.31 0.25 0.32 0.38 0.37 
ALR2 0.15 0.14 0.08 0.13 0.15 0.14 0.15 0.15 
AMPC 0.33 0.29 0.33 0.32 0.33 0.32 0.33 0.33 
AR 0.17 0.16 0.17 0.17 0.17 0.18 0.17 0.18 
CDK2 0.21 0.20 0.19 0.19 0.19 0.21 0.19 0.20 
COMT 0.50 0.41 0.50 0.46 0.50 0.41 0.50 0.46 
COX1 0.20 0.21 0.10 0.17 0.20 0.21 0.20 0.17 
COX2 0.36 0.35 0.39 0.36 0.41 0.38 0.44 0.39 
DHFR 0.29 0.31 0.29 0.27 0.36 0.34 0.36 0.34 
EGFR 0.33 0.31 0.35 0.34 0.38 0.36 0.40 0.37 
ERagonist 0.50 0.46 0.50 0.47 0.50 0.46 0.50 0.47 
ERantagonist 0.25 0.29 0.38 0.31 0.25 0.31 0.38 0.36 
FGFR1 0.33 0.30 0.25 0.28 0.33 0.34 0.25 0.29 
FXA 0.18 0.19 0.21 0.19 0.21 0.20 0.21 0.20 
GART 0.40 0.30 0.20 0.18 0.20 0.15 0.20 0.15 
GPB 0.22 0.26 0.33 0.28 0.22 0.25 0.33 0.29 
GR 0.25 0.21 0.25 0.22 0.25 0.20 0.25 0.24 
HIVPR 0.50 0.50 0.33 0.42 0.67 0.67 0.67 0.67 
HIVRT 0.17 0.13 0.08 0.12 0.08 0.12 0.08 0.14 
HMGA 0.50 0.45 0.50 0.45 0.50 0.54 0.50 0.57 
HSP90 0.50 0.46 0.50 0.52 0.50 0.51 0.50 0.51 
INHA 0.17 0.20 0.22 0.22 0.22 0.22 0.22 0.23 
MR 0.50 0.50 0.50 0.50 0.50 0.50 0.50 0.50 
NA 0.29 0.27 0.29 0.28 0.29 0.31 0.29 0.32 
P38 0.37 0.31 0.32 0.31 0.37 0.34 0.37 0.34 
PARP 0.25 0.23 0.33 0.25 0.25 0.23 0.25 0.25 
PDE5 0.24 0.25 0.19 0.20 0.29 0.28 0.19 0.23 
PDGFRB 0.29 0.30 0.26 0.29 0.29 0.31 0.29 0.31 
PNP 0.67 0.70 0.67 0.58 0.67 0.75 0.67 0.75 
PPARG 0.42 0.36 0.50 0.44 0.33 0.33 0.58 0.53 
PR 0.33 0.32 0.33 0.32 0.33 0.33 0.33 0.32 
RXRA 0.67 0.61 0.67 0.57 0.67 0.57 0.67 0.61 
SAHH 1.00 0.76 1.00 0.77 1.00 0.83 1.00 0.85 
SRC 0.25 0.28 0.20 0.23 0.25 0.29 0.25 0.26 
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Thrombin 0.31 0.26 0.23 0.26 0.15 0.21 0.23 0.28 
TK 0.14 0.21 0.29 0.27 0.29 0.28 0.29 0.29 
Trypsin 0.25 0.23 0.17 0.21 0.17 0.19 0.17 0.19 
VEGFR2 0.08 0.10 0.08 0.09 0.08 0.12 0.08 0.11 
average 0.33 0.31 0.33 0.31 0.33 0.33 0.35 0.34 
median 0.29 0.31 0.30 0.28 0.29 0.31 0.30 0.30 
 
In order to investigate the differences between the different 
targets, average ROC curves (Nicholls 2008) were plotted. In ten 
cases, there is no difference or it is extremely small. The data set 
is too small for six targets (GART, HIVPR, MR, PPARG, RXRA 
and TRYPSIN). The remaining 24 ROC curves are shown in 
Figure 7.10. In DHFR, HMGA, PNP, SAHH data sets, the 
MULTI_MULTI approach clearly outperforms others. There are 
also some cases where the use of single conformation databases 
yields better results (ERagonist, FGFR1, PDGFRB and SRC). 
Overall, there is no clear pattern between target type and the 
approach with highest ROC AUC. 
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Figure 7.10: Average ROC curves for SINGLE_SINGLE (solid gray line), 
SINGLE_MULTI (solid black line), MULTI_SINGLE (dotted gray line) and 
MULTI_MULTI (dotted black line). (1 of 4) 
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Figure 7.10: Average ROC curves for SINGLE_SINGLE (solid gray line), 
SINGLE_MULTI (solid black line), MULTI_SINGLE (dotted gray line) and 
MULTI_MULTI (dotted black line). (2 of 4) 
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Figure 7.10: Average ROC curves for SINGLE_SINGLE (solid gray line), 
SINGLE_MULTI (solid black line), MULTI_SINGLE (dotted gray line) and 
MULTI_MULTI (dotted black line). (3 of 4) 
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Figure 7.10: Average ROC curves for SINGLE_SINGLE (solid gray line), 
SINGLE_MULTI (solid black line), MULTI_SINGLE (dotted gray line) and 
MULTI_MULTI (dotted black line). (4 of 4) 
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To determine whether the arbitrarily selected cutoff for the top 
molecules (two times the number of ligands per target) had any 
effect on the results, average curves of fraction of retrieved 
scaffolds in different cutoffs were plotted. The maximum curve 
in this plot is the case, where every unique scaffold is retrieved 
from the top of the hitlist. A random curve is generated from a 
shuffled hitlist. It can be concluded that the selection of the 
cutoff did not have any effect on the conclusions, as the graphs 
of different approaches are similar for most targets. Graphs for 
two targets (COX2 and EGFR) with large numbers of ligands 
and scaffolds are shown in Figure 7.11 as an example. 
 
 
Figure 7.11: Fraction of retrieved scaffolds represented as a function of fraction of 
screened database for COX2 and EGFR. SINGLE_SINGLE (solid gray), 
SINGLE_MULTI (solid black), MULTI_SINGLE (dotted gray) and MULTI_MULTI 
(dotted black) produce similar results. Maximum is drawn with dashed line and 
random with dashed dotted line. 
 
The small variation between the approaches might be related to 
the issue of the number of starting positions. Different 
conformations of the same molecule most likely have a similar 
effect on the results as increasing the number of starting 
positions, as there were minor differences found between 
various initialization modes in the PAPER article by Haque and 
Pande.  
Conformation generation revealed an imbalance in DUD LIB 
VS, as the ligands had fewer conformations (8.9) than the decoys 
(12.4) on average and it is possible that this has skewed the 
results. However, no correlation was found between the 
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difference in conformations per molecule and the target median 
ROC AUC of any of the conformational analysis approaches 
(Figure 7.12). 
 
 
Figure 7.12: Target median ROC AUC vs. the fraction between average number of 
ligand conformations and the average number of decoy conformations. 
 
Various query molecules for different targets produce extremely 
poor ROC AUC values, which are independent of the 
conformational analysis strategy. These ROC AUCs are often 
related to small query molecules. As previously discussed, it 
makes little sense to align a small query molecule against much 
larger molecules (see Chapter 2.6). Some kind of quick pre-
filtering step should be applied to the database before the actual 
shape-based virtual screening in order to eliminate these kinds 
of pairs, so that the computationally more intensive molecular 
alignment process could be omitted for these cases. 
Even though the ROC AUC values and fraction of retrieved 
scaffolds are rather similar, the ShapeTanimoto scores of 
different approaches are clearly different with different 
conformational analysis approaches (Table 7.7). The more 
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computation effort that is used, the higher are the 
ShapeTanimoto scores. However, the difference between ligand 
and decoy sets stays approximately the same, which explains 
the similar virtual screening accuracy (Table 7.8). Similar 
observations have been made when comparing simple shape 
descriptors like USR and ROCS (Nicholls et al. 2010). It is 
possible that the ligands and decoys are separated to some other 
factors that are not very sensitive to the shape of the molecules. 
Therefore enrichment metrics seem to be a poor measure of the 
quality of the alignment algorithm. 
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Table 7.7: Average ShapeTanimoto similarity for ligand (L) and decoy (D) sets. 
 SS SM MS MM 
Target L D L D L D L D 
ACE 0.49 0.48 0.57 0.56 0.56 0.56 0.62 0.62 
ACHE 0.56 0.49 0.64 0.56 0.64 0.58 0.70 0.63 
ADA 0.66 0.61 0.70 0.67 0.70 0.66 0.77 0.72 
ALR2 0.57 0.58 0.62 0.63 0.61 0.62 0.66 0.67 
AMPC 0.60 0.54 0.69 0.61 0.69 0.66 0.77 0.71 
AR 0.75 0.63 0.77 0.68 0.77 0.65 0.79 0.69 
CDK2 0.56 0.53 0.62 0.61 0.62 0.59 0.67 0.66 
COMT 0.53 0.55 0.57 0.59 0.57 0.60 0.61 0.63 
COX1 0.63 0.61 0.65 0.65 0.65 0.63 0.67 0.67 
COX2 0.64 0.50 0.69 0.57 0.69 0.53 0.73 0.60 
DHFR 0.59 0.54 0.69 0.64 0.68 0.62 0.76 0.69 
EGFR 0.63 0.57 0.68 0.64 0.68 0.61 0.72 0.68 
ERagonist 0.73 0.64 0.74 0.69 0.74 0.66 0.75 0.70 
ERantagonist 0.55 0.42 0.61 0.54 0.61 0.52 0.66 0.59 
FGFR1 0.55 0.48 0.60 0.57 0.59 0.52 0.64 0.60 
FXA 0.47 0.41 0.58 0.52 0.58 0.51 0.69 0.60 
GART 0.52 0.46 0.63 0.58 0.63 0.58 0.76 0.69 
GPB 0.66 0.59 0.71 0.65 0.71 0.65 0.75 0.69 
GR 0.60 0.53 0.63 0.58 0.63 0.56 0.66 0.61 
HIVPR 0.41 0.38 0.50 0.48 0.50 0.46 0.61 0.56 
HIVRT 0.51 0.52 0.59 0.59 0.59 0.59 0.66 0.65 
HMGA 0.50 0.45 0.57 0.53 0.57 0.53 0.66 0.59 
HSP90 0.57 0.49 0.66 0.58 0.66 0.56 0.73 0.64 
INHA 0.58 0.52 0.65 0.60 0.65 0.60 0.71 0.66 
MR 0.78 0.59 0.78 0.63 0.78 0.61 0.80 0.65 
NA 0.58 0.51 0.62 0.58 0.62 0.55 0.67 0.61 
P38 0.58 0.52 0.64 0.58 0.64 0.57 0.69 0.62 
PARP 0.66 0.63 0.70 0.67 0.69 0.67 0.72 0.70 
PDE5 0.54 0.45 0.60 0.53 0.59 0.50 0.64 0.57 
PDGFRB 0.63 0.56 0.67 0.63 0.66 0.60 0.69 0.66 
PNP 0.64 0.58 0.71 0.66 0.71 0.62 0.77 0.70 
PPARG 0.47 0.43 0.56 0.51 0.55 0.52 0.64 0.58 
PR 0.68 0.56 0.71 0.62 0.72 0.60 0.76 0.65 
RXRA 0.63 0.51 0.66 0.58 0.67 0.54 0.72 0.61 
SAHH 0.73 0.63 0.80 0.70 0.60 0.54 0.64 0.61 
SRC 0.55 0.49 0.60 0.58 0.60 0.54 0.64 0.61 
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Thrombin 0.52 0.44 0.57 0.53 0.57 0.52 0.64 0.60 
TK 0.68 0.65 0.75 0.71 0.75 0.71 0.80 0.76 
Trypsin 0.53 0.44 0.56 0.54 0.56 0.52 0.65 0.61 
VEGFR2 0.53 0.51 0.60 0.60 0.60 0.57 0.65 0.65 
mean 0.59 0.53 0.65 0.60 0.65 0.59 0.70 0.64 
median 0.58 0.52 0.64 0.59 0.65 0.58 0.69 0.64 
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Table 7.8: Average difference in ShapeTanimoto between ligand and decoy sets. 
Target SS SM MS MM 
ACE 0.008 0.003 0.001 -0.004 
ACHE 0.068 0.077 0.060 0.066 
ADA 0.050 0.032 0.034 0.050 
ALR2 -0.005 -0.019 -0.009 -0.016 
AMPC 0.062 0.073 0.024 0.060 
AR 0.118 0.095 0.119 0.097 
CDK2 0.032 0.019 0.027 0.018 
COMT -0.020 -0.023 -0.027 -0.021 
COX1 0.018 -0.008 0.017 -0.005 
COX2 0.142 0.118 0.156 0.129 
DHFR 0.050 0.050 0.063 0.071 
EGFR 0.062 0.042 0.067 0.048 
ERagonist 0.086 0.048 0.082 0.049 
ERantagonist 0.103 0.071 0.090 0.069 
FGFR1 0.075 0.032 0.074 0.038 
FXA 0.060 0.061 0.073 0.091 
GART 0.057 0.053 0.046 0.075 
GPB 0.071 0.056 0.059 0.053 
GR 0.071 0.051 0.068 0.052 
HIVPR 0.029 0.016 0.037 0.051 
HIVRT -0.003 0.000 0.003 0.007 
HMGA 0.044 0.041 0.048 0.066 
HSP90 0.083 0.077 0.095 0.089 
INHA 0.052 0.052 0.049 0.050 
MR 0.187 0.151 0.172 0.151 
NA 0.071 0.046 0.072 0.057 
P38 0.061 0.055 0.070 0.065 
PARP 0.025 0.025 0.022 0.025 
PDE5 0.087 0.066 0.097 0.074 
PDGFRB 0.074 0.038 0.067 0.036 
PNP 0.059 0.044 0.082 0.078 
PPARG 0.044 0.059 0.037 0.060 
PR 0.116 0.093 0.120 0.107 
RXRA 0.119 0.085 0.122 0.116 
SAHH 0.093 0.096 0.104 0.107 
SRC 0.058 0.020 0.058 0.027 
Thrombin 0.081 0.039 0.051 0.045 
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TK 0.031 0.042 0.033 0.044 
Trypsin 0.083 0.020 0.040 0.040 
VEGFR2 0.019 -0.001 0.021 0.002 
mean 0.063 0.047 0.061 0.055 
median 0.062 0.047 0.060 0.053 
 
A low ShapeTanimoto value does not necessarily mean an 
unreasonable alignment. This is illustrated in Figure 7.13, where 
there are two COX2 inhibitors superimposed with different 
conformational analysis approaches. Even though the 
SINGLE_SINGLE alignment looks reasonable enough, it has a 
low ShapeTanimoto score of 0.683 because the benzene rings are 
in different orientations on both molecules. 
 
 
Figure 7.13: Valdecoxib (black) superimposed to ZINC00006596 (gray). 
 
Although PAPER algorithm is extremely fast (0.1-0.3 ms per 
alignment), the large variations in the numbers of alignments 
create significant differences in the required computation time 
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between the different conformational analysis approaches 
(Table 7.9). By using a multi-conformation database with a 
single conformation query, one must align ten times more 
molecules than with single conformation database. The use of a 
multi-conformation query with multi-conformation database 
increases the number of alignments by almost two orders of 
magnitude compared to the simplest approach. The generation 
of multi-conformation databases also adds to the computational 
expense of SINGLE_MULTI and MULTI_MULTI approaches. 
 
Table 7.9: The number of alignments in this study for each conformational analysis 
approach. 
Approach Alignments Increase Factor 
SINGLE_SINGLE 13253166 1.0 
SINGLE_MULTI 144375674 10.89 
MULTI_SINGLE 97157157 7.33 
MULTI_MULTI 1114373810 84.08 
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8 Conclusions 
Ligand-based virtual screening based on alignment and 
simple models derived from molecular fields might be 
feasible. A novel virtual screening method called FieldChopper 
was developed. It is based on the discretization of the 
electrostatic and van der Waals field into three classes. The 
results from retrospective virtual screening experiments suggest 
that FieldChopper is competitive with more complex descriptors 
and could be used as a molecular sieve when multiple ligands 
are known. However, it is obvious that additional work would 
be required to make the software more relevant to drug 
discovery projects. A major obstacle to the further development 
of FieldChopper is the lack of high quality data sets that fulfill 
the requirement of similar ligand binding mode. This effectively 
prevented the study of using FieldChopper for the rapid 
prediction of ADMET-properties (notably metabolism), which 
was one planned application area of the original project. 
 
The use of several query ligands in alignment-based virtual 
screening improves results considerably. In the FieldChopper 
evaluation, it was discovered that by using several query 
molecules with EON, clearly superior results compared to single 
alignments with FieldChopper could be achieved. However, this 
strategy increased the computation time by approximately 
1500% i.e. it requires considerably more computing resources as 
the number of active compounds and the size of the database 
increase. After the publication of this study, Kirchmair and co-
workers reported that this observation applies to all targets in 
DUD (Kirchmair et al. 2009).  
 
Tautomerism prediction is not an issue in current structure-
based virtual screening. It was shown that more accurate 
treatment of tautomerism did not have a dramatic effect on a 
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current structure-based virtual screening method. The culprit 
for poor performance must be sought elsewhere. Given the 
limited accuracy of current scoring functions, the use of multiple 
tautomeric and protonation states of the ligands is simply a 
waste of time and resources.  
 
The use of single conformation databases may be feasible in 
shape-based virtual screening. The use of single conformation 
databases for the PAPER method yields comparable results to 
more elaborate multi-conformational virtual screening 
strategies, as measured by ROC AUC and the fraction of 
retrieved scaffolds. By using single conformation databases, one 
can significantly decrease the need for computing resources, 
especially when working with large databases containing very 
flexible molecules. This is however only an initial observation 
and needs to be investigated in more detail. During the 
preparation of this thesis, a perspective article by Nicholls and 
co-workers was published (Nicholls et al. 2010).  They showed 
that even though shape-descriptor USR and ROCS 
ShapeTanimoto had approximately the same ROC AUC values 
for DUD, the correlation between the two similarity scores was 
poor. It was suggested that there is some other feature in the 
data set in addition to the shape that differentiates ligands from 
decoys. Whatever the reality may be, new virtual screening 
benchmarks are urgently needed to study such peculiar 
observations. 
 
Enrichment metrics can be misleading in virtual screening 
method development. Although the aim of virtual screening is 
always to find active ligands from a large pool of inactive 
molecules, enrichment metrics are problematic in method 
development. The quality of alignments was significantly 
poorer when using single conformational databases with 
PAPER, but this was not evident from simply calculating the 
enrichments. In addition, the problem of analog bias and 
scaffold definitions should be investigated in more detail. 
151 
 
  
 
GPU-computing has a great potential for both ligand- and 
structure-based methods. As a side product from this study, a 
publicly available command line interface was developed for 
PAPER, which makes it possible for anyone to align large sets of 
molecules on regular desktop computers. At the time of writing 
of this thesis, GPU software for virtual screening was virtually 
unavailable. It is very likely that these kinds of programs will 
become commonly available in the near future. 
 
Structure-based virtual screening has serious limitations. The 
same issues remain in molecular docking from year to year, 
which can be seen by comparing review articles from the last 
eight years (Lyne 2002; Kitchen et al. 2004; Köppen 2009; Kolb 
and Irwin 2009). There is still the fundamental question if 
docking is actually useful or are the results obtained from 
prospective screens more or less due to chance, as the hits from 
the screens are rarely validated by experimental procedures 
(Leach et al. 2006; Nicholls 2008; Kolb and Irwin 2009). Perhaps 
the huge increase in parallel computing in recent years may 
alleviate this issue by allowing more sophisticated methods to 
be used than the current scoring functions. However, as the 
understanding of protein-ligand interactions is still rather 
limited (Whitesides and Krishnamurthy 2005), there is still 
much basic research to be done to overcome the current 
limitations. Given that docking is still a rather computationally 
intensive task, it might be wise to first to use ligand-based 
techniques if possible. 
 
3D-methods should be used evaluated more. There is still an 
on-going discussion about whether the computationally more 
demanding 3D methods can actually confer any extra value 
compared to simple 2D-methods like fingerprints (Eckert and 
Bajorath 2007; Zhang and Muegge 2006; Brown and Martin 1996, 
1997; Makara 2001; Sciabola et al. 2007; McGregor and Muskal 
1999, 2000; Jenkins et al. 2004; Good et al. 2004b; Nettles et al. 
2006; Tiikkainen et al. 2009).  It is clear that additional 
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investigations are needed to establish the putative benefits of 
3D-virtual screening. 
Finally, currently the development and evaluation of virtual 
screening methods is challenging due to the lack of standards. 
In order to improve current methods, it is imperative that such 
guidelines are quickly established by the scientific community. 
The author would like to end this thesis by quoting Anthony 
Nicholls of OpenEye Scientific Software: “Whether the modeling 
community has the will to enact such measures may well determine 
whether future generations of scientists look back and see a field that 
became essential to drug discovery or one that became a mere footnote” 
(Nicholls 2008). 
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